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CHAPTER I
INTRODUCTION

Neurotrophic factors (NTFs) represent a unique class of
proteins that are involved specifically in neuronal
development and the survival. of mature neurons. They also
exert an important effect on lesion-induced neuronal
plasticity. These actions of NTFs may provide a key to
developing pharmacological agents for the treatment of
neurodegenerative diseases.
In neurodegenerative diseases such as Senile Dementia
of the Alzheimer type (SDAT) and Parkinson's disease (PD),
neurons atrophy, become dysfunctional, and ultimately die.
In these diseases there is a loss of neurons and their
associated neurotransmitters from specific regions of the
brain. In SDAT, cell loss occurs in the basal forebrain
[medial septum (MS), substantia innominata, hippocampus,
amygdala], while in PD, neurons in the substantia nigra die.
This cell loss results in a deficiency of the neurotransmitters acetylcholine (ACh) and dopamine, respectively, in
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these patients. The loss of cholinergic neurons in SDAT
patients is thought to be responsible for producing the
deficits in memory and cognition experienced by these
patients (Hefti 1994). Since neuronal death occurs in these
diseases and because NTFs are known to be important in the
survival of adult neurons, it has been proposed that the use
of NTFs represents a plausible therapy in the treatment of
these diseases (Koliatsos et al. 1993; Lindsay et al. 1994;
Hefti 1994) .
Recently several NTFs have been isolated including
Nerve Growth Factor (NGF) , basic Fibroblast Growth Factor
(bFGF), Brain Derived Neurotrophic Factor (BDNF), Neurotrophin-3

(NT-3), and Neurotrophin-4

(NT-4). NGF was the

first of these to be isolated and has been shown to act on
several groups of cholinergic neurons located in the basal
forebrain. One such group of neurons is the septohippocampal pathway (SHP) . In this pathway, the fimbriafornix (FF) connects the septum and hippocampus. When the FF
is surgically transected, there is a loss of cholinergic
neurons and their associated phenotypic markers (Hefti 1986;
Lapchak, Araujo, and Hefti 1992) . The similarity in the
reduction of cholinergic phenotypic markers in the SHP to
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changes in SDAT patients, and its well defined anatomical
structure, make this pathway an appropriate region to test
the in vivo effects of NTFs on cholinergic neurons.
Several studies have evaluated the effects of NGF on
the loss of cholinergic neurons in the SHP. NGF can reverse
the loss of choline acetyltransferase (ChAT) immunoreacti vity (IR) and acetylcholinesterase (AChE) staining
induced by transecting the FF (Hagg et al. 1989; Kromer
1987; Montero and Hefti 1988; Otto, Frotscher, and Unsicker
1989; Anderson et al. 1988). This work on compromised
cholinergic neurons in the SHP has led to the proposed use
of NGF specifically for the treatment of SDAT (Hefti and
Schneider 1989).
Although NGF has been shown to be effective in
reversing the reduction in cholinergic phenotypic markers
that occur in FF transected rats, studies investigating the
effects of NGF on normal cholinergic neurons are not
conclusive. Some studies indicate that NGF does not affect
these neurons (Williams, Jodelis, and Donald 1989; Hefti,
Dravid, and Hartikka 1984). In contrast, other studies have
demonstrated that NGF does affect normal cholinergic neurons
of the SHP, although these effects appear to be less than
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those seen in compromised neuronal systems (Fusco et al.
1989; Williams 199la). These studies indicate that more work
is needed in evaluating the effects of NGF on normal, noncompromised, cholinergic neurons. Furthermore, dose and time
response experiments of the effects of NGF on normal neurons
have not been previously conducted and are necessary if NGF
is to be considered for use as a treatment for SDAT.
In addition to NGF, two other NTFs have been shown to
affect cholinergic neurons of the basal forebrain region.
bFGF, like NGF, has been shown to be capable of reversing
decreases in cholinergic phenotypic markers in the SHP
induced by transecting the FF (Otto, Frotscher, and Unsicker
1989; Anderson et al. 1988). BDNF, a more recently isolated
NTF (Liebrock et al. 1989), has also been shown to affect
cholinergic neurons. Much of this work has shown that, in
culture, BDNF promotes the survival of septal cells. In
contrast, there are conflicting reports as to whether

in

vivo BDNF administration affects cholinergic neurons (Morse
et al. 1993; Lapchak, Araujo, and Hefti 1992).
Although both bFGF and BDNF act on cholinergic neurons
of the basal forebrain, these two NTFs are not as well
characterized as NGF. Neither bFGF nor BDNF have been eval-
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uated as to their effects on normal cholinergic neurons, in

vivo.
Further investigation is needed to determine the
effects of NGF, bFGF, and BDNF on normal cholinergic
neurons. A comparison of the effects of these three NTFs on
normal neurons, as well as on neurons with decreased
cholinergic phenotypic markers, is important for their
possible future use as therapeutic agents in the treatment
of neurodegenerative diseases. Further, the current
knowledge of NTFs and their effects indicate that
cholinergic neurons with reduced phenotypic markers may be
more sensitive to exogenous NTFs than normal neurons.
The goal of this dissertation was to investigate the

in vivo effects of various NTFs on both normal and
compromised cholinergic neurons of the SHP.
In these studies, the neurotoxin AF64A (ethylcholine
aziridinium ion) was used to investigate the effects of NTFs
on cholinergic neurons with reduced enzyme activity in the
SHP. AF64A has been shown to produce decreases in
cholinergic enzyme activity in neurons of the SHP (Fisher et
al. 1982; El Tamer et al. 1992). AF64A is selective for
cholinergic neurons of the SHP and provides a more specific
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method of decreasing cholinergic phenotypic markers than FF
transection. Therefore, AF64A represents a novel approach to
evaluating whether cholinergic neurons, whose activity has
been altered, are more sensitive to exogenously administered
NTFs than normal

(non-compromised) neurons.

The following hypotheses were tested in this work:
1) Exogenous NTFs, when administered in vivo to adult rats,
stimulate ChAT and AChE activity in normal cholinergic
neurons.
2) When alterations in neuronal cholinergic enzyme activity
are created by AF64A, the affected neurons have an
increased sensitivity to exogenous NTF administration.
These hypotheses have allowed the following questions to be
addressed:
1) Do various NTFs affect the enzyme activity of normal
cholinergic neurons in the SHP? What is the dose and time
relationship between NTF administration and changes in
cholinergic enzyme activity? Are they the same for all
the NTFs or are they different?
2) Are the changes in enzyme activity selective for
cholinergic neurons or do they also occur in other
neurotransmitter systems?
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3) Does AF64A treatment increase the sensitivity of
cholinergic neurons of the BHP to exogenous NTFs?

Specific Aims
Two specific aims were addressed in this project.

Specific Aim # 1:
EFFECT OF INTRACEREBROVENTRICULAR ADMINISTRATION OF
NTFs ON NORMAL CHOLINERGIC NEURONS OF THE SEPTO-HIPPOCAMPAL
PATHWAY.
la) Determine if NTFs (NGF, bFGF, BDNF), when administered
intracerebroventricularly (i.c.v.), affect cholinergic
neurons in the BHP of normal rats.
In order to evaluate the effects of these trophic
factors on cholinergic neurons, the levels of ChAT and AChE
activity in the SHP were measured after i.c.v. administration of the three NTFs. Dose response studies for NGF and
BDNF were conducted. Further, the time course relationship
between NGF administration and changes in cholinergic enzyme
activity in normal rats was examined.
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lb) Determine if NTFs (NGF and BDNF) , when administered
i.c.v., affect non-cholinergic neurons in the SHP of normal
rats.
In order to evaluate the selectivity of NTFs for
cholinergic neurons, their affect on glutamic acid
decarboxylase (GAD) activity in the SHP was measured.

S~ecific

Aim# 2:

THE IN VIVO EFFECT OF AF64A TREATMENT ON THE ABILITY OF
NTFs TO AFFECT CHOLINERGIC NEURONS OF THE SEPTO-HIPPOCAMPAL
PATHWAY.
Determine if AF64A treatment prior to NTF administration influences the effects that NTFs have on cholinergic
enzyme activity in the SHP.
The NTFs were administered after i.c.v. injection of
AF64A and cholinergic enzyme activity was measured.
Concurrently, NGF's effect on cholinergic enzyme activity in
striatal tissue was measured. This allowed for the
comparison of the effects of NGF in two populations of
cholinergic neurons, one which is sensitive to AF64A (the
SHP) and one which is not {the striatum) .

CHAPTER I I
LITERATURE REVIEW

Neurotrophic Factors
NTF proteins are known to be important in the
development and maintenance of neurons. Several of these
NTFs (BDNF, NT-3, and NGF) are known to have up to 50% amino
acid sequence homology and comprise a family of NTFs called
neurotrophins (Lapchak, Araujo and Hefti 1992). Although
similar in structure, they are thought to exert selectivity
by binding to distinct receptors. In addition to the
neurotrophins, other proteins such as bFGF, which are not
similar in structure, also have trophic actions on the
neurons in the CNS.

Nerve Growth Factor
Nerve growth factor was the first trophic factor to be
discovered and is the prototypical NTF. NGF is a polypeptide
which is found in the CNS as well as in a limited number of
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10
non-neural tissues such as the mouse submaxillary gland
(Ayer-Lelievre et al. 1983). NGF is a precursor molecule
which is cleaved to a final, 118 amino acid protein with 6
cystine residues f orrning three disulfide bonds (Angeletti
and Bradshaw 1991) . NGF is composed of two a, one
y subunit

(Young et al. 1988).

The~

~'

and one

subunit (2.5 S) is the

biologically active portion of the peptide (Lapchak, Araujo
and Hefti 1992; Varon et al. 1988).
Although NGF was initially thought to be important in
neuronal development, it now appears that NGF's main role is
in the survival and maintenance of neurons. This is indicated by the temporal expression of NGF messenger ribonucleic acid (mRNA) and receptors. As early as postnatal day
one, immunoreactivity for NGF receptors is found in the
hippocampus, MS/diagonal band complex (DBC), and striatum
with peak values found at postnatal day 10 followed by a
subsequent reduction to adult levels (Koy and Loy 1989).
Complementary to NGF receptor expression, NGF mRNA in the
hippocampus follows a similar pattern. On postnatal day two,
expression is low but increases to adult levels by postnatal
day 20. These temporal sequences of expression indicate that
NGF is primarily important for the survival of mature
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neurons (Lauterborn et al. 1994a).
Immunoreactivity for NGF in the adult is found in areas
with large populations of cholinergic neurons such as the
cerebral cortex, MS/DBC, hippocampus and striatum (Senut et
al. 1990; Mufson et al. 1994; Alberch et al. 1991). Further,
NGF mRNA expression follows a similar regional pattern with
high levels of expression in the hippocampus and cortex
while low levels occur in the septum and striatum (Lauterborn et al. 1994a; Shelton et al. 1986; Korsching et al.
1985). Regional differences in the expression of NGF are
found within the hippocampus. The highest levels are seen in
the dentate gyrus and cornu Ammonis (CA)3-4 regions while
lower levels are found in the CAl-2 regions (Lauterborn et
al. 1994a; Korsching et al. 1985). The distribution of NGFIR and mRNA is consistent with the idea that NGF is a
target-derived trophic factor,

since one would expect a high

level of NGF-IR in the MS/DEC and the hippocampus but only
high levels of the mRNA in the hippocampus.
The expression of NGF and its mRNA in the brain is
responsive to changes in neuronal activity. Activity induced
by excitatory amino acids increases endogenous expression of
NGF in the hippocampus (Gall et al. 1991). Further,
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electrolytic lesions produce an increase in hippocampal NGF
mRNA (Gall et al. 1989), NGF-like-IR and NGF activity (Scott
et al. 1994). NGF levels are also increased in both the
hippocampus (95%) and septum (250%) after the FF is
transected (Weskamp et al. 1986).
Increases in endogenous NGF may also be due to
stimulation of cholinergic neurons. Quisqualate
administration (which produces excitation) into the MS/DBC
produces an increase in NGF mRNA in the hippocampus. This
increase can be blocked by the cholinergic antagonist,
scopolamine (Lindefors et al. 1992) and indicates that
cholinergic neuronal activity in this region may regulate
NGF expression.
NGF acts via a postsynaptic receptor which has both a
high and low affinity component. It is now recognized that
there are two receptors which bind NGF. One is the high
affinity receptor called TrkA (pl40)

(Kd-10- 11M) and the

other is the low affinity receptor, p75 (Kd-10- 9 M) . TrkA is
formed from the proto-oncogene trk (Kaplan et al. 1991) and
is a 140 KD membrane spanning protein specific for NGF.
Further, it is TrkA which is responsible for the biological
activity induced by NGF (Lapchak et al. 1992; Varon et al.
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1988). TrkA is a tyrosine kinase receptor (Kaplan et al.
1991) and therefore stimulation with NGF produces autophosphorylation of the tyrosine residues. This autophosphorylation contributes to producing the response seen
in neurons treated with NGF and can be blocked by the kinase
inhibitor K252a (Maher et al. 1989).
The regional localization of the NGF receptor is
similar to that of the NGF protein and its mRNA. In adult
rats, NGF receptors have been colocalized by immunocytochemistry with cholinergic neurons in the MS/DBC,
striatum and hippocarnpus (Koy and Loy 1989; Hagg et al.
1989; Mufson et al. 1994; Taniuchi et al. 1986; Woolf, Gould
and Butcher 1989) . NGF receptor immunoreactivity has 92%
colocalization with ChAT positive neurons in the basal
forebrain (Woolf, Gould and Butcher 1989).
After binding to the receptor, NGF is transported in a
retrograde manner (Ferguson et al. 1991; Taniuchi et al.
1986) . If usI-NGF is injected into the lateral ventricle,
the MS/DBC becomes reactive. Peak reactivity occurs 18 hours
post injection but traces of the isotope in the MS/DBC can
be seen as early as five hours. The binding and accumulation
of NGF into the MS/DBC region is specific since the addition
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of an excess amount of cold NGF inhibited this binding and
transport. Further, NGF is rapidly cleared from the brain by
30 hours after i.c.v. injection.

(Ferguson et al. 1991).

Although NGF's action is mediated via receptor binding,
its intracellular mechanism of action is still unknown. One
possible mechanism may be through second messengers. In

vitro work has demonstrated that NGF stimulates a variety of
second messengers such as calcium
1986), cAMP

(CA2 ~)

(Alonso et al.

or inositol triphosphate (Knipper et al. 1993).

In addition it appears that the immediate early gene, c-fos,
may also play a role. When exogenous NGF is administered to
neurons, c-fos expression increases (Kruijer et al. 1985).
Administration of exogenous NGF can alter cholinergic
markers in rats with neuronal injury. Transection of the FF
has been used extensively to create reductions in cholinergic phenotypic markers in BHP neurons. Transection of the FF
results in a reduction of ChAT and AChE (=50-80%) in both
the MS and hippocampus (Lapchak and Hefti 1991; Hefti 1986;
Armstrong et al. 1987; Matthews et al. 1987; Gage et al.
1988) . Exogenously applied NGF into the lateral ventricle
can almost completely attenuate the loss of these
cholinergic phenotypic markers (up to 70% sparing of
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neurons)

(Hagg et al. 1989, Kromer 1987; Montero et al.

1988; Gage et al. 1988) and produces a hypertrophic response

in the size of MS cells (Vahlsing et al. 1991).
Williams, Jodelis, and Donald (1989) have shown that
normal, unaltered, cholinergic neurons in the septum of
normal rats do not respond to exogenous NGF, while those in
animals with complete FF transections appear to be
"supersensitive" to NGF. NGF, in FF transected rats,
increased ChAT activity 200% higher then in normal animals.
Furthermore, a similar effect on ChAT activity has been
found in animals that have had partial FF transections
(Hefti Dravid and Hartinkka 1984i Gage et al. 1988).
Surprisingly, it has been shown that AChE activity is
unaffected by NGF in the septum of either transected or
non-transected animals (Williams, Jodelis and Donald 1989;
Hefti 1986) .
In contrast, other studies indicate that normal,
unaltered, cholinergic neurons in the MS/DBC of adult rats
are responsive to exogenously applied NGF. Fusco et. al,
(1989)

have shown that NGF administration to intact rats

increases ChAT activity in the MS (79%) and hippocampus
(43%)

in a dose dependent manner. Similar to previous
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reports (Williams, Jodelis and Donald 1989), NGF did not
change AChE activity in either of these regions. In addition
to increasing ChAT activity in the SHP of normal rats (Fusco
et al. 1989; Vantini et al. 1986; Williams and Rylett 1990),
NGF also increases high affinity choline transport (HAChT)
in the hippocampus (Williams and Rylett 1990) .

Brain Derived

Neurotro~hic

Factor

Unlike NGF, BDNF has only recently been isolated and
cloned (Barde et al. 1982; Leibrock et al. 1989). BDNF is
similar in structure to NGF, and their amino acid sequences
show a high degree of homology including a group of six
cystine residues (Leibrock et al. 1989). Like NGF, BDNF is a
basic protein

(pI~l0.1)

with 112 amino acids and a molecular

weight of approximately 12.3 kDa (Barde et al. 1982).
The expression of BDNF appears to be specific to
neuronal tissue since it is not expressed in peripheral
tissue such as kidney, lung, liver, heart, muscle, and
spleen (Leibrock et al. 1989). Within the brain, BDNF mRNA
has been localized to several specific regions including the
hippocampus, piriform cortex, hypothalamus, cerebellum,
olfactory nucleus, claustrum, temporal cortex, basolateral
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amygdala, and the pars compacta of the substantia nigra
(Phillips et al. 1990; Wetmore et al. 1990; Ernfors et al.
1990a; Boatell et al. 1992). BDNF mRNA appears to be highest
in the hippocampus, where the largest level of expression
occurs in the pyramidal cell layer of CAl-4, the hilus, and
the granular cells of the dentate gyrus (DG) (Ernfors et al.
1990a; Phillips et al. 1990; Wetmore et al. 1990; Boatell et
al. 1992). The expression of BDNF mRNA appears to be
mediated by neuronal activity. Hilar lesions and administration of excitatory amino acids can increase the level of
BDNF mRNA expression in the hippocampus (Zafra et al. 1990;
Isackson et al. 1991; Ballarin et al. 1991; Boatell et al.
1992). This up-regulation in expression appears to be
modulated by cholinergic neurons. It has been shown that the
muscarinic receptor agonists, pilocarpine or carbachol
produce increases in BDNF mRNA expression while the
antagonists, scopolamine or atropine, can block these
effects (Berzaghi et al. 1993; Zafra et al. 1990).
BDNF binds to a specific, 145 kd, glycoprotein
receptor, TrkB. Like the TrkA receptor, TrkB is a tyrosine
kinase receptor and is therefore capable of phosphorylating
tyrosine residues on proteins. trkB mRNA is localized to
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specific regions of the brain including the diencephalon,
hypothalamus, basal ganglia, basal forebrain, hippocampus
(pyramidal and granule layers), substantia nigra, amygdala,
neocortex (II-VI)

(Altar et al. 1994c), choroid plexus,

ependymal cells of the ventricles, and glial cells (Yan et
al. 1994). Immunohistochemical studies indicate that trkB is
localized in the wall of the lateral ventricle, choroid
plexus, pia mater, and cells in the parenchyma (Yan et al.
1994).
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I-BDNF binds to cortex, septum, hippocampus,

cerebellum and the walls of the lateral ventricle (Altar et
al. 1994c; Yan et al. 1994). This localization of the trkB
receptor is similar to that of BDNF mRNA or its protein and
therefore the receptor and BDNF are probably coexpressed
(Kokaia et al. 1993). Although BDNF does not bind to the
high affinity NGF receptor (trkA) it does appear to bind to
the low affinity (p75) receptor. This binding is not
necessary for the action of BDNF and is thought to be due to
the similarities in amino acid sequences between BDNF and
NGF.
Although BDNF is not as well characterized as NGF,
studies have been conducted both in vitro and in vivo in
order to determine the action of BDNF on neurons. In
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culture, BDNF has been shown to affect cells from various
brain regions. This is not unexpected since BDNF, unlike
NGF, is widely distributed in the brain. In vitro survival
of cortical neurons appears to be due to the action of BDNF.
When antibodies to BDNF are introduced into the culture,
cell atrophy occurs, survival decreases and there is a loss
of dendritic branching (Ghosh et al. 1994). When BDNF is
applied to cultures of basal forebrain cells, their survival
as well as production of cholinergic phenotypic markers
(ChAT, AChE, and HAChT) increases (Alderson et al. 1990;
Nonomura and Hatanaka 1992}. The action of BDNF is not
limited to cholinergic neurons; it also promotes tyrosine
hydroxylase staining in 6-hydroxydopamine (6-0HDA) or Nmethyl-4-phenylpyridinium ion (MPP+) treated mesencephalic
neurons (Spina et al. 1992).
Recently, work has been conducted to investigate BDNF's
effect in vivo in rats. BDNF has been shown to prevent the
effects of FF transection on cholinergic neurons in the
septum when administered intraseptally (Morse et al. 1992,
1993) or by i.c.v. injection (Knusel et al. 1992). In
contrast, other work has demonstrated that BDNF does not
restore phenotypic markers of cholinergic activity (ACh,
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ChAT activity, HAChT, ChAT-IR) in the septum after FF
transection (Lapchak et al. 1992; Koliatsos et al. 1994).
BDNF also does not affect cholinergic markers in the nucleus
basalis of Meynert (nbM) or cortex after lesion of these
areas (Skup et al. 1994; Dekker et al. 1994). From these
current reports, BDNF may or may not act on cholinergic
neurons in vivo. The differences found in the effects of
this NTF may be accounted for by its distribution when
administered. Work with

125

1-BDNF has shown that when

injected into the lateral ventricle, BDNF binds to the
ependymal layers whereas when administered intraseptally, it
is localized to the dorsal septum near the injection site
(Morse et al. 1993). This would make sense since the trkB
receptor is also localized to the ependymal cells that line
the wall of the lateral ventricles. Such findings indicate
that BDNF may play a role in the functioning of cholinergic
neurons of the SHP.
BDNF administration to other regions of the brain
indicates that cholinergic neurons may not be the only
populations of neurons affected by BDNF. Supranigral
administration of BDNF to 6-0HDA lesioned rats attenuates
behavioral impairments and the reduction of dopaminergic
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metabolites that occur in these animals (Altar et al.
1994b) .

Fibroblast Growth Factor
Fibroblast growth factor is a neurotrophic factor
that occurs in basic and acidic forms. Of these two forms,
the action of basic fibroblast growth factor (bFGF) on the
brain has been studied in greater detail. Unlike NGF, bFGF
has a more ubiquitous distribution in the brain. Basic
fibroblast growth factor mRNA has been localized to the
cortex, septum, hippocampus, olfactory bulb, superior and
inferior colliculus and pituitary (Ernfors et al. 1990a;
Powell et al, 1991; Riva et al. 1994). This expression is
similar to the immunoreactivity for the bFGF protein.
Matsuyama et al. (1992) reported that bFGF-IR is found in the
cerebellum, red nucleus and reticular formation, cortex,
olfactory bulb, septum, DBC, and hippocampus. Within the
hippocampus, the granule cells of the dentate gyrus and
pyramidal cells in the CA2-3 regions have the highest levels
of bFGF-IR (Matsuyama et al. 1992; Gomez-Pinilla et al.
1992) .
In agreement with the localization of bFGF mRNA and its
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protein, mRNA for the bFGF receptor is also localized to the
cortex, hippocampus, brain stem and cerebellum (Wanaka et
al. 1990). Surprisingly the regional expression in the
hippocampus of the bFGF receptor mRNA is different from that
which is found for the bFGF protein. The receptor mRNA is
more highly concentrated in the CA3-4 regions while the DG
and CAl, CA2 regions have a lower level of mRNA expression
(Wanaka et al. 1990; Gomez-Pinilla et al. 1992). This
regional expression of bFGF receptor mRNA agrees with the
binding characteristics of
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1-bFGF when administered into

the ventricles. The usr-bFGF binding is localized to the
cortex, hippocampus (pyramidal cells of the CAl-3 regions) ,
thalamic nuclei and hypothalamus. Surprisingly, no labeling
was found in the basal forebrain region (Ferguson et al.
1991).
The expression of bFGF in the brain appears to be
developmentally regulated. Basic fibroblast growth factor
mRNA reaches its peak expression in the brain at embryonic
day 16 and then decreases to its adult level (Ernfors et al.
1990b) . The bFGF receptor mRNA follows a similar pattern and
is most highly expressed at embryonic days 13-17 before it
decreases to adult levels (Powell et al. 1991).
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Although bFGF is expressed endogenously in the brain,
this expression can be regulated or modified. Like other
trophic factors, neuronal activity appears to be a mediator
of endogenous expression. Rats which received electroshock
showed an increase in bFGF mRNA expression in the
hippocampus, olfactory bulb, cerebellum and entorhinal
cortex (Follesa et al. 1994). Further, chemical agents, such
as kainate, which induce neuronal activity also increase the
neuronal expression of bFGF. Intraperitoneal injection of
kainate into rats increased expression of bFGF mRNA, bFGF
and its receptor in the hippocampus (Riva et al. 1994; Van
Der Wal et al. 1994). Increased endogenous expression of
bFGF and its associated proteins may be due to increased
production from astrocytes, since bFGF and its associated
proteins correlate with glial f ibrillary acidic protein
staining (Gomez-Pinilla et al. 1992) in these regions.
Basal forebrain cholinergic neurons are known to be
stimulated by exogenously applied bFGF. Basic fibroblast
growth factor administration to septa! cell cultures
increases ChAT activity, AChE staining and cell density
(Knusel et al. 1990; Kushima et al. 1992). These increases
are specific for bFGF since they can be blocked by selective
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antibodies (Knusel et al. 1990).
In parallel with the in vitro work done, in vivo

bFGF

administration indicates that this NTF is important in the
maintenance of cholinergic neurons in the MS/DBC and their
recovery after FF transection. Like NGF, when bFGF is
administered after FF transection, ChAT-IR, AChE staining,
and cell survival in the MS/DBC is increased compared with
controls (Otto et al. 1989; Anderson et al. 1988). Exogenous
bFGF also reduces the loss of NGF receptor positive neurons
in the MS/DBC from 60% to only
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(Gomez-Pinilla et al.

1992; Schwaber et al. 1991). Further, bFGF attenuates the
loss of ChAT activity seen in the hippocampus (Barette et
al. 1989; Araujo et al. 1993) but, in contrast to the work
with NGF, does not alter the loss of other presynaptic
cholinergic markers such as the synthesis and release of ACh
(Araujo et al. 1993). Exogenously applied bFGF can also
reverse the loss of tyrosine hydroxylase staining that
occurs within the striatum after the neurotoxin, 1-methyl-4phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)

is administered

(Otto et al. 1990). This, as well as the regional
distribution of bFGF, indicates that bFGF may not be as
selective as NGF for cholinergic neurons but may act on
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other neurotransmitter systems as well.

Anatomy of the Septo-Hippocampal Pathway
The septo-hippocampal pathway originates from the
septal nucleus/DEC (vertical and horizontal limb) which
projects via the fimbria fornix to the hippocampal formation
(Butcher and Woolf 1986) . The main neurotransmitters found
within this pathway are ACh and y-aminobutyric acid (GABA),
(Leranth et al. 1992; Witter 1986) although other
neurotransmitters, such as norepinephrine, serotonin and
dopamine are also present (Hortnagl et al. 1991).
Acetylcholine is synthesized from the precursor choline
and acetyl Coenzyme A by the enzyme ChAT (Taylor and Brown
1989). ChAT is synthesized in the septal cell bodies as
demonstrated by the localization of its mRNA to this region
(Ibanez et al. 1991; Lauterborn et al. 1993). ChAT is
located throughout the entire neuron since it is transported
to the terminal region in the hippocarnpus where it
synthesizes ACh. ACh is metabolized in the synaptic cleft by
the enzyme AChE into choline and acetic acid. Choline is
transported into the cell terminal by sodium dependent
HAChT. The level of choline and its uptake into the neuronal
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terminal represents the rate limiting step in the production
of ACh (Taylor and Brown 1989) . The neurochemicals
associated with the cholinergic neurons are useful markers
for determining the anatomical distribution of neurons which
express ACh.
GABA is an inhibitory neurotransmitter and plays a role
in the regulation of neuronal activity. GABA is synthesized
from L-glutamic acid by the enzyme GAD and the cofactor,
pyridoxal-5'-phosphate, in the terminal

(McGeer and McGeer

1989) . GAD is located in the synaptosome of neurons and its
restriction to GABAergic neurons make it a reliable marker
for GABA (Martin and Rimvall l993; Storm-Mathisen 1978). The
activity of GABA is stopped by either sodium dependent
uptake or the enzyme, GABA transaminase. As in the case of
cholinergic neurons, the neurochemicals of the GABAergic
neurons are used as anatomical and functional markers for
these neurons. Further, parvalbumin is also used to
determine the location of GABAergic neurons since it has
been shown to be colocalized with GABA in the SHP (Freund
1989).
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The Septal Region
The subcortical septal area consists of four main
regions: 1) lateral; 2) medial; 3) ventral; and 4) posterior
(Swanson 1978). The lateral region can be further separated
into dorsal, intermediate and ventral areas and is comprised
of medium size neurons. The medial region consists of two
sub-areas, the medial septal nuclei and diagonal band
complex. These nuclei are made up of both small and large
neurons. The ventral region mainly consists of the bed
nucleus of stria terminalis and is composed of a population
of large heterogenous neurons. Finally the posterior region
consists of two cell groups, the septo-fimbria and
triangular nuclei (Swanson 1978).
In the MS/DBC region, neurons are immunoreactive for
both ChAT (Amaral and Kurz 1985) and parvalbumin (Kiss et al
1990; Leranth et al. 1992). Further, they exhibit both ChAT
and GAD activity (Fonnum 1977) . These two markers are not
colocalized in the same neurons. Parvalbumin positive
neurons are predominantly located in the intermedial portion
of the medial septum while CbAT positive neurons are located
laterally. In contrast to the septum, with its localized
concentration of parvalbumin staining, the parvalbumin
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positive cells in the DBC are widely scattered (Kiss et al.
1990; Freund 1989).

The Hippocampal Region
The hippocampal formation can be divided into several
regions. These include the CA, DG, and subiculum. These
regions have a laminar organization which is defined by
three distinct cell layers. The cellular organization in the
CA region is composed of the molecular layer (small
neurons), pyramidal layer (large neurons), and polymorphic
layer. The DG cellular organization is similar, with the
exception of the pyramidal layer which is replaced by a
granular layer (small neurons)

(Witter 1986) . The CA region

and the subiculum form part of the pre- and postcommissural segments of the fornix system, while the DG
gives rise primarily to intra-hippocampal connections.
The hippocampus expresses both ChAT (Reine et al. 1992)
and GAD activity (Reine et al. 1992; Martin and Rimvall
1993; Hortnagl et al. 1991). The ChAT activity probably
originates in the septum since ChAT mRNA is undetectable in
the hippocampus (Ibanez Ernfors and Persson 1991; Lauterborn
et al. 1993). It is possible that cholinergic interneurons
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also contribute to the level of ChAT activity in the
hippocampus since ChAT-IR is seen in this region (Wainer et
al. 1985; Matthews et al. 1987). In addition to GAD
activity, hippocampal neurons are also immunoreactive for
the GAD protein (Brady and Vaughn 1988; Reine et al. 1992)

Septo-hippocampal Pathway Connections
Many studies have been conducted to investigate the
innervation between the septal/DBC and the hippocampal
formation. Fibers from the MS/DBC have been shown to
terminate in various regions of the dorsal hippocampus
including the infragranular and granular layers of the
dentate gyrus, CA3-4 regions, and the molecular layer of the
subiculum (Witter 1986; Rose, Hattori, and Fibiger 1976;
Baisden , Woodruff, and Hoover 1984; Amaral and Kurz 1985).
The ventral hippocampus receives fibers from the lateral
portion of the MS and dorsolateral portion of the DBC. These
connections are both cholinergic (Toth 1993; Wainer 1985;
Okayama et al. 1987) and GABAergic (Leranth 1992) as
indicated by retrograde labeling with horseradish
peroxidase, cholinergic and GABAergic markers. Even though
these neurons express different neurotransmitters, they are
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similar in structure and morphological characteristics
(Naumann, Linke, and Frotscher 1992) .
The SHP is a reciprocal pathway with the hippocampus
projecting back to the septum. The topography of this
reciprocal innervation includes the pyramidal cells in the
CAl, CA3, and subiculum regions of the dorsal hippocampus
projecting to the dorsomedial lateral septal nuclei. The
ventral hippocampus projects to the ventrolateral portion of
the lateral septum (Witter 1986; Leranth et al. 1992). These
projections are thought to be primarily ipsilateral, but a
small component is bilateral. A large percentage (94%) of
antrogradely labeled neurons in the medial and lateral
septum are immunoreactive for GABA (Toth et al. 1993). These
afferents have connections with both parvalbumin and ChAT
positive neurons (Toth et al. 1993).

Senile Dementia of the Alzheimer Type (SDAT)
Symptoms and Clinical Criteria
Dementia due to Alzheimer's disease represents
approximately 50% of all clinically defined cases of
dementia (Blennow and Wallen, 1994) . The prevalence of SDAT
has increased over recent years due to the overall aging of
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the general population. Currently, 10-15% of the population
over age 65 will be diagnosed as having SDAT {Bondareff
19 94) .
Patients present a host of symptoms which imply, but do
not definitively diagnose, that they have SDAT. The
classical symptoms of SDAT include loss of memory, reduced
cognitive abilities, and changes in personality. Although a
definitive diagnosis is not possible until death, criteria
have been established to make a diagnosis of probable SDAT.
These criteria, formulated by the National Institute for
Neurological and Communicative Disorders and Stroke, are:
dementia {determined by clinical exam and neuropsychological
test) with deficits in two or more areas of cognition,
progressive worsening of memory and cognition, no
disturbance in consciousness, and onset after age 65.
Further these symptoms must occur in the absence of systemic
disorders and other brain diseases that would cause changes
in cognition and memory (McXhann et al. 1984). Early in the
disease the dementia is mild and patients continue to live
independently. As the dementia becomes more pronounced,
patients can no longer live independently and require
chronic care. The life expectancy in patients with SDAT is
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usually 5-6 years less than that of the general population
(Blennow and Wallen, 1994).

Neuropathology
At present, the only definitive diagnosis of SDAT
occurs after the patient dies and a histopathological
examination can be made (McKhann et al. 1984). Several
neuropathological features, which were originally
characterized by Alois Alzheimer in 1907, remain the most
positive means of establishing whether a patient had SDAT.
One of these is the abnormal accumulation of proteins which
form neuritic plaques and neurofibrillary tangles (Hefti and
Mash 1989; Glenner 1989). The plaques and tangles accumulate
primarily in the cortex, amygdala, and hippocampus regions
of the brain (Cordell 1994).
Neuritic plaques are formed from an accumulation, in
the parenchyma of neurons, of a 39-42 amino acid protein
known as

~-amyloid.

This protein is produced from a

precursor known as the amyloid precursor protein (APP)

When

the APP is cleaved it can produce either a soluble (via a
secretase enzyme) or a non-soluble (via a lysosome pathway)
form of

~-amyloid

(Hardy and Higgins 1992; for review see
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Cordell 1994). Since

~-amyloid

is also produced in people

without SDAT, it has been postulated that SDAT patients have
a predisposition to accumulate the non-soluble form of the
protein.
The neurofibrillary tangles are made up of paired
helical filaments which are composed of the protein, tau
(Kosik et al. 1992). These filaments are thought to be
formed through an abnormally high level of phosphorylation
of the protein, Tau. Recent evidence that this
phosphorylation may be due to the

~-amyloid

expressed with the tangles. In vitro,

which is co-

~-amyloid

induces

abnormal phosphorylation of the tau protein in cortical and
hippocampal tissue (Cordell 1994).
Although both plaques and tangles have been well
described, why these distinct features occur in the brains
of SDAT patients is uncertain. Further, whether these
phenomena represent the cause of the disease, or are a
consequence of some previous event in the cascade of this
disease is still unknown.
In addition to the plaques and tangles associated with
SDAT, a large amount of neuronal loss also occurs in select
regions of the brain. This loss occurs from the nbM, MS, and
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hippocampus located in the basal f orebrain region
(Whitehouse et al. 1982; West et al. 1994)

SDAT patients

have up to a 79% cell loss in these regions (Whitehouse et
al. 1982). The neuronal loss represents a decrease of
cholinergic neurons in these regions and a loss of ACh in
the terminals of these neurons. A reduction in the
cholinergic markers, ChAT, AChE, and HAChT has been
demonstrated in the hippocampus, frontal cortex, and
substantia innominata of patients with SDAT (Nagel et al.
1983; Davies and Maloney 1976; Rylett, Ball, and Colhoun
1983; Giacobini 1990; Hefti and Mash 1989). Although this
neuronal loss is primarily of cholinergic neurons, markers
for other neurotransmitters, such as norepinephrine, GABA,
serotonin, dopamine and glutamate (Glenner 1989) also
decrease in Alzheimer patients.

Animal Models
One of the problems in Alzheimer's research is the lack
of an appropriate animal model for SDAT. Many investigators
have endeavored to mimic the loss of cholinergic neurons of
the basal forebrain in animals. This has been attempted by
either surgical transection or the use of chemical toxins.
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When the FF is surgically transected there is a loss of
neurons in the MS as well as a decrease in cholinergic
phenotypic markers from the entire SHP (Montero et al. 1988;
Hagg et al. 1989). Lesioning the nbM-cortical pathway also
results in neuronal loss and decreases in cholinergic
neurons (Santucci et al. 1993).
The reduction of cholinergic phenotypic markers in
basal forebrain neurons has also been attempted with various
chemicals which are toxic to these neurons. When excitatory
amino acids are administered into the brain, they have been
shown to produce neuronal destruction (Santucci, Kanof, and
Haroutunian 1993; Unger and Schmitt 1992). One problem with
using excitatory amino acids is that the neuronal loss
produced is non-specific. In addition to cholinergic
neurons, other neuronal types are also decreased.
In contrast to the non-specific damage caused by
excitatory amino acids, the neurotoxin AF64A (ethylcholine
mustard aziridinium) produces a more selective reduction in
cholinergic phenotypic markers in the SHP. These include the
loss of cholinergic markers such as ChAT, AChE and HAChT
activity (El Tamer et al. 1992), as well as a loss of ChAT
positive cells in the medial septum (Lorens et al. 1991). In
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addition to the reduction of cholinergic markers, animals
treated with AF64A also demonstrate behavioral changes and
memory deficits (Chrobak et al. 1987).
Aged rats show some anatomical and neurochemical
changes similar to SDAT patients. They have neuronal atrophy
and cell loss as well as a reduction in basal forebrain
cholinergic markers (Mervis et al. 1991; Williams and
Rylett, 1990). Further these rats show memory deficits when
tested on behavioral tasks. In contrast to SDAT patients,
aged rats do not develop plaques and tangles and therefore
are not an ideal model.
Since models of reduced cholinergic function do not
mimic the plaques and tangles seen in SDAT, investigators
have tried to mimic these neuropathological signs by
injecting

~-amyloid

directly in the brain of rats.

~-amyloid

has been shown to be toxic to neurons both in vitro and in
vivo. In vitro, administration of the

~-(1-40)

segment of

APP produced a decrease in the survival of hippocampal
neurons (Yankner et al. 1990). When this same fragment was
injected into either the cortex or hippocampus, neuronal
loss and neuritic degeneration were produced (Kowall et al.
1991). Further, in vivo infusion of

~-(1-40)

into the
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cerebral cortex produced ALZ-50 immunoreactivity in the
cortex seven days later. Since ALZ-50 recognizes the
phosphorylated form of tau, there may be an association
between

~-amyloid

and tau which is found in tangles.

Interestingly, although this model produces amyloidal
plaques and cell loss, it does not demonstrate changes in
cholinergic neuronal functioning.

Current Treatment for SPAT
The unknown etiology of SDAT has hampered efforts to
devise an effective treatment for this disease. The lack of
understanding as to the origin of the disease has promoted
treatment strategies which are designed to address the
various symptoms of the disease.
The current therapy strategy is based on the assumption
that the cholinergic deficit seen in the brains of SPAT
patients is responsible for the cognitive and memory
impairments. As discussed previously in this dissertation,
the cholinergic system is linked intricately with
neurochemical and behavioral changes seen in SPAT patients.
Further, memory deficits can be induced in normal volunteers
by administering a muscarinic receptor antagonist (Prachman
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and Leavitt 1974). Therefore, many of the therapies have
been aimed at providing the basal forebrain with additional
ACh. This has been attempted through the use of ACh
precursors (choline or lecithin) and AChE inhibitors such
as: physostigmine, tetrahydroaminoacridine (tacrine), or
huperzine (Hanin 1993). Further, therapy with muscarinic
agonists such as bethanechol, AF102B, and arecoline has also
been used in attempts to treat patients (Hanin 1993; Kan
1992). Of these treatments, the use of AChE inhibitors has
produced some moderate benefits, but unfortunately, they may
also produce liver toxicity (Kan 1992; Cordell 1994).
Several lines of evidence indicate that NTFs may be
useful as therapeutic agents in the treatment of SDAT. NGF
and BDNF are highly localized to the basal forebrain region
(Phillips et al. 1991; Senut et al. 1990) where most of the
cell loss occurs in SDAT patients. In addition to NTFs being
located in the basal f orebrain, receptors for NGF are also
found in this region in both normal and SDAT patients (Hefti
1989; Strada et al. 1992; Kordower et al. 1989). Further,
these NTFs have been shown to act on cholinergic neurons of
this brain region and NGF has been specifically shown to
produce changes in the neurochemical function of these
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neurons, prevent cell death and promote behavioral recovery.
Work in animals with NGF has led to the limited use of
NGF in SDAT patients. NGF was administered to a SDAT patient
and produced improved responses on several neuroanatomical
and behavioral parameters (Olson et al. 1992). Prior to
treatment the subject had several typical symptoms of SDAT
including decreased cortical nicotinic binding, decreased
brain blood flow, and poor cognitive abilities. NGF infusion
into the right lateral ventricle of this patient improved
all of these measures (Olson et al. 1992). Unfortunately,
these improvements were temporary and three months after NGF
treatment was discontinued, the disease continued to
progress with all of these measures decreasing to levels at
or below those seen prior to NGF treatment (Olson et al.
1992). Further, this treatment produced pain as a side
effect. This work indicates that NTFs may be useful in the
future as therapeutic agents in neurodegenerative diseases,
but that more studies are still necessary before reaching
such a desirable stage.
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AF64A
AF64A has been proposed as a selective toxin for
cholinergic neurons. The work with AF64A has been directed
towards developing an in vivo model of cholinergic
deficiency in the brain (Hanin 1994) . The development of a
cholinodef icient animal model would be useful for testing
proposed therapeutic agents which may stimulate the
production of ACh in cholinergic neurons

Neurochemical Effects of AF64A in the Brain
When administered into the brain, AF64A alters several
cholinergic markers including ChAT, AChE, ACh, and HAChT.
AF64A decreases all of these markers by approximately 50% in
the hippocampus after AF64A treatment (Potter et al. 1989;
El Tarner et al. 1992; Chrobak et al. 1988; Chrobak et al.
1987; Ikegarni et al. 1989; Opello et al. 1993). AF64A
administration also significantly reduces potassium induced
release of ACh in hippocampal slices (Leventer et al. 1985).
These changes in cholinergic markers occur as soon as two
days after administration of AF64A and last up to 180 days
(El Tamer et al. 1992).
In contrast to the decrease in cholinergic enzyme
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activity in the hippocampus, AF64A has been shown to
transiently increase septal ChAT activity by 45%. This
increase occurs two to seven days post AF64A administration
and returns to control levels by 14 days (El Tamer et al.
1992). In addition to the changes that occur in the enzyme
activity in the septum there are also changes in the number
of ChAT-IR cells which remain in this region. Twenty eight
days after AF64A treatment, the number of ChAT-IR cells were
reduced 31-51% (Lorens et al. 1990; Chrobak et al. 1988).
This reduction occurred in a selective population of septal
neurons. The intermediate group was the most sensitive to
AF64A while the ventral neurons were insensitive. This
decrease in ChAT-IR is attributed to a loss of neurons since
there is also a loss of fluro-gold labeling of these neurons
(Dong et al. 1992).
Cholinergic neurons in the striatum may also be
sensitive to AF64A treatment depending on the dose and route
of toxin administration. Rats treated by i.c.v. injection
with AF64A (1-5 nmol) showed no change in ChAT or AChE
activity (Moos et al. 1991; Leventer et al. 1985), HAChT,
mACh receptor binding (Leventer et al. 1985) or ACh levels
(Hortnagl 1987a; Chrobak et al 1987; Chrobak et al. 1988,
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Opello et al. 1993; Potter et al. 1989) in the striatum. On
the other hand, at very high doses

(65 nmol), i.c.v.

administration of AF64A produced a reduction in ACh, HAChT
and ChAT activity (Fisher et al 1982) in the striatum of
mice. The decrease in cholinergic markers in the striatum
after i.c.v. administration of a high dose of AF64A (65
nmol) is transient with recovery by day 21. In addition, if
AF64A (0.1-10 nmol) is administered directly into the
striatum there is a loss of AChE staining, ChAT activity,
HAChT and ACh (McGurk et al. 1987; Sandberg et al. 1983).
These decreases in the cholinergic markers in the striatum
after AF64A occur in a dose dependent manner (McGurk et al.
1987).

Effect on Non-Cholinergic Neurons
Although AF64A has clearly been shown to reduce
cholinergic phenotypic markers in the SHP when administered
by i.c.v. injection, other neurotransmitter systems can also
be affected, in a secondary and transient manner. AF64A
administration reduces markers for the serotonergic and
noradrenergic systems. Serotonin (5-HT) and its metabolite,
5-hydroxy-indole acetic acid (5-HIAA), are reduced in the
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hippocampus after i.c.v. AF64A (2-5 nmol) administration
(Hortnagl 1987b). In addition to 5-HT, AF64A also reduces
norepinephrine (NE)

(Hortnagl et al. 1987a; Potter et al.

1989) and glutamate levels (Hortnagl et al. 1991) in the
hippocampus.
The effects of AF64A on non-cholinergic neurons are
dose dependent. Changes in non-cholinergic markers are
transient

(Hortnagl et al. 1987a,b; Chrobak et al. 1988)

compared with those that occur for up to 180 days in cholinergic neurons (El Tamer et al. 1992). These short term
changes in the serotonergic and noradrenergic systems are
occur secondary to changes in cholinergic neurons. Evidence
for this is provided by the observations that hemicholinium3 (HC-3) or its analog, A4, block the changes that occur in
both the cholinergic system as well as other neurotransmitter systems (Potter et al. 1989). Stimulation of muscarinic receptors by pilocarpine prevents the decrease of
glutamate in the hippocampus that occurs after AF64A
treatment (Hortnagl 1991). Further, the changes in 5-HT are
highly correlated with changes that occur in the cholinergic
terminals in the hippocampus (H6rtnagl et al. 1987a).
AF64A administration does not change the level of other
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neurotransmitter systems in the hippocampus or septum. The
dopaminergic system is not affected by AF64A administration.
The levels of dopamine (DA) are neither reduced nor
increased in the hippocampus of rats treated with AF64A
(Hortnagl 1987a). In the septum, parvalbumin levels,
indicative of GABAergic neurons, are not changed by i.c.v.
AF64A administration (Dong et al. 1994).
In the striatum, as in the hippocarnpus, i.c.v. AF64A
reduces 5-HT levels in a transient manner (Hortnagl et al.
1987a,b). When AF64A (8 nmol) was administered directly into
the striatum, GAD and tyrosine hydroxylase activity were not
reduced significantly (Sandberg et al. 1984). In contrast, a
higher dose of AF64A (12 nmol) produced deficits in GAD and
TH activity in the striatum.
Changes in non-cholinergic striatal neurons are dose
dependent requiring long term administration of high doses
of AF64A. Additionally, some of these changes may be due to
the non-specific tissue damage, such as neuritic cavitation,
that is produced when very high doses of AF64A are injected
directly into the tissue (McGurk et al. 1987).
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Effects on Behavior and Memory
In addition to its action on cholinergic neurons, AF64A
alters the behavior of rats, causing them to become
hyperactive, jumpy and more aggressive than controls
(Ikegami et al. 1991; Leventer et al. 1985).
Rats treated with AF64A by i.c.v. injection perform
poorly on behavioral tests compared with controls. In the
Morris water maze task, rats treated with AF64A by i.c.v.
injection had a greater latency time in finding the
platform, took a longer path to the platform, and spent less
time in the target area (platform)

(Opello et al. 1993;

Armstrong et al. 1991). These difficulties indicate a
deficit in spatial memory. AF64A has also been shown to
impair the working memory of rats. AF64A injected rats
perform more poorly than controls on behavioral tasks such
as the T-maze and eight arm radial maze (Chrobak et al.
1987; Chrobak et al. 1988). These deficits in memory, as

determined by behavioral tests, indicate that AF64A induces
both changes in cholinergic markers and memory.
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Structure and Toxicity
AF64A is structurally similar to choline (fig. 1)
with the exception that two methyl groups on the nitrogen
are cyclized into an aziridinium ring and a methyl group is
extended into an ethyl group. This similarity in structure
is believed to allow AF64A to act at the HAChT site on the
terminals of cholinergic neurons. The effects of AF64A on
cholinergic neurons are thought to be brought about by its
action on the presynaptic terminals of these neurons since
i.c.v. administration reduces cholinergic presynaptic
markers (ChAT, HAChT and ACh) but not post synaptic markers
such as muscarinic receptors (Fisher et al. 1982) in the
hippocampus. Further, its toxic effects can be prevented by
pretreatment with choline (Fisher et al. 1982) or HC-3
(Potter et al. 1989) which compete with AF64A for uptake
into the neuron via the HAChT route.
Although AF64A's structural similarity to choline
allows it to be selective for cholinergic neurons, the
differences between their structures impart the necessary
component to induce toxicity to the neurons (Hanin 1990) .
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The aziridinium ring which is formed during the synthesis of
AF64A from its precursor AF64

(acetylethyl choline mustard

hydrochloride) appears to be the structural component that
produces AF64A's toxic effect. In vitro experiments
comparing AF64A with either its precursor (AF64) or products
without the aziridinium ring, indicate that these were three
times less effective than AF64A in inhibiting HAChT in
hippocampal synaptosomes (Hortnagl et al. 1988). This
corresponds to the action of AF64A in vivo where AF64A
reduced ACh content in the hippocampus by 68% while the
precursor or products without the aziridinium ring only
produced a 28-41% reduction (probably after partial
formation of the aziridinium ring in vivo) (Hortnagl et al.
1988).

Recovery from AF64A
Although AF64A produces deficits in cholinergic markers
when administered in vivo, some of these deficits are
reversible. Administration of AF64A (3 nmol/lateral
ventricle) produced long term decreases in ChAT and AChE
activity as well as HAChT in the hippocampus. These
decreases lasted up to 180 days before their levels returned
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to control (El Tamer et al.1992). The ability of cholinergic
markers to recover is dose dependent (0.5 - 1.5 nmol/
ventricle) since rats treated with lower doses had their
cholinergic markers return to control levels earlier than
those treated at higher doses. Recovery of AF64A-induced
cholinergic deficits (decrease in hippocampal ChAT) also
occurred in newborn rats injected post-natal day two, whose
ChAT levels returned to control after 58 postnatal days
(Armstrong and Pappas 1991).
In addition to spontaneous recovery, recovery of
cholinergic markers, as well as behavioral measures, can
also be induced by transplantation of basal forebrain
tissue. Rats transplanted with either septal or nbM fetal
tissue after AF64A treatment showed less reduction in
cholinergic markers (HAChT, AChE staining, and ChAT
activity) than AF64A treated rats which did not receive such
transplants (Ikegami et al. 1989; Ikegami et al. 1991;
Emerich et al. 1992). Further, in rats treated with AF64A
and then receiving fetal transplants, there was an
improvement in the performance on behavioral tasks (open
field activity and radial arm maze) in comparison with rats
only treated with AF64A (Ikegami et al. 1989; Ikegami et al.
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1991; Emerich et al. 1992).
Various chemical substances have also been used in
attempts to reverse the action of AF64A on cholinergic
neurons. In vitro AF64A reduces ChAT activity in rat brain
aggregates. If NGF is administered after a two day delay,
ChAT activity returns to control levels (Atterwill and
Meakin 1990). In vivo, vitamin E, bFGF, NGF, ganglioside
GMl, transforming growth factor a

(TGF a) and epidermal

growth factor (EGF) have been used in an attempt to produce
recovery of AF64A decreases in cholinergic markers in the
SHP. AF64A induced behavioral deficits, as well as the
reduction in hippocampal ChAT and HAChT activity, were
reversed by vitamin E (Wortwein et al. 1994; Johnson et al.
1988) . In addition, bFGF has also been shown to reverse
AF64A induced decreases in hippocampal ChAT activity (Potter
and Morrison 1991). In contrast, neither NGF, TGF a, GMl or
EGF reversed the AF64A induced decrease in hippocampal
cholinergic markers (Johnson et al. 1988; Potter and
Morrison 1991) .

CHAPTER III
BASIC FIBROBLAST GROWTH FACTOR IN AF64A TREATED RATS FAILS
TO INCREASE CHOLINERGIC ENZYME ACTIVITY IN THE SEPTOHIPPOCAMPAL PATHWAY

Summary
Previous in vitro and in vivo work indicates that bFGF
may play a role in the regulation of cholinergic neurons and
their phenotypic markers. In the present study, i.c.v.
administration of bFGF to AP64A treated rats did not produce
any changes in ChAT or AChE activity in the hippocampus. In

AF64A/bFGF (0.006 nmol) treated rats, septal ChAT activity
remained unchanged while AChE activity decreased 34%
compared with AF64A/CC treated rats. In addition, AF64A/bFGF
treated rats had normal weight gain over the 14 days of
treatment. This weight gain was comparable with that seen in
the control (AF64A/CC) rats. These data indicate that bFGF
has limited influence on cholinergic enzyme activity in the
SHP of AF64A treated rats.
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Introduction
Basic fibroblast growth factor is a mitogen with a
widespread distribution in the brain. Basic fibroblast
growth factor like-IR has been localized to the cortex,
caudate-putamen, hypothalamus, septum (medial and lateral)
and hippocampus (dentate gyrus, CA2 and subiculum
regions) (Matsuyama et al. 1992). Basic fibroblast growth
factor is thought to be produced locally since its mRNA is
also found in these regions (hypothalamus, cortex,
hippocampus, septum and striatum) (Powell et al. 1991;
Ernfors et al. 1990b). The bFGF receptor, which is necessary
for the action of bFGF, is also located in the cerebral
cortex, hippocampus, cerebellum and brain stem. Surprisingly, the bFGF receptor is not found in the septum or
striatum (Wanaka, Johnson, and Milbrandt 1990). Several of
these regions (particularly the septum and hippocampus) with
high levels of bFGF mRNA and immuno-reactivity also have a
large number of cholinergic neurons. This may indicate that
bFGF plays a role in the survival of cholinergic neurons.
In vitro, bFGF administration produced an increase in

the survival of cholinergic basal forebrain cells.
Administration of bFGF to septal cell cultures increases
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ChAT-IR (Knusel et al. 1990) and ChAT activity (Yokoyama et
al. 1994; Knusel et al. 1990). The action of bFGFs on ChAT
activity in septal cultures is specific since it can be
blocked by a bFGF antibody but, not an NGF antibody (Knusel
et al. 1990). Basic fibroblast growth factor also increased
cell proliferation (Knusel et al. 1990) and the number of
AChE positive cells (Kushima et al. 1992) in septal
cultures.
When administered in vivo, bFGF appears to have a role
in recovery from neuronal damage. Administration of bFGF
(8.0 µg) partially attenuated the loss of ChAT-IR that
occurred in the MS after the FF was transected (Otto,
Frotscher, and Unsicker 1989). This effect is similar to,
but not as large as, those seen with NGF (Otto, Frotscher,
and Unsicker 1989). In vivo bFGF (0.084 µg)

administration

can reduce the loss of AChE staining in the MS/DBC that
occurs after the FF is transected (Anderson et al. 1988).
The loss of hippocampal ChAT activity due to partial FF
transection can be partially prevented by injection of 0.020.01 µg bFGF into the lateral ventricle (Barotte et al.
1989; Araujo, Lapchak, and Hefti 1993).
In the brain, bFGF also appears to be protective
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against chemical insults. The loss of striatal dopamine
after MPTP treatment is partially reversed by bFGF
administration (Otto and Unsicker 1990) . In addition, bFGF
has been shown to protect against the toxic effects of the
cholinotoxin, AF64A (Potter and Morrison 1991) . Administration of AF64A into the lateral ventricles produces a
decrease in cholinergic phenotypic markers in the
hippocampus (El Tamer et al. 1992; Leventer et al., 1985;
Potter and Morrison 1991) . These reductions in cholinergic
markers can be attenuated by i.c.v. administration of
0.084 µg bFGF (Potter and Morrison 1991).
The current study focuses on the effect of in vivo
administration of bFGF on cholinergic neurons in the SHP of
AF64A treated rats. Basic fibroblast growth factor administration did not stimulate cholinergic enzyme activity in
the hippocampus or septum of AF64A treated rats. Basic
fibroblast growth factors lack of action on cholinergic
enzyme activity in the SHP is in contrast to the actions of
other growth factors such as NGF or BDNF.
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Materials and Methods
Animals
Adult, male Sprague-Dawley rats (Zivic Miller
Laboratories, Allison Park, PA.) weighing between
188-324 grams were used for this study. They were housed two
per cage in a room on a 12 hour light cycle and had access
to food and water ad libitum. A total of 24 rats were used
in this study. The rats were weighed at the time of surgery,
on day 7, and on day 14. These rats were used under the
auspices of the IACUC.

AF64A
AF64A was prepared according a standard procedure
(Fisher et al. 1982). Briefly, acetylethylcholine mustard
hydrochloride (UCB, Belgium) was dissolved in water to a
concentration of 0.667 mM. This solution was adjusted to pH
11.5 with sodium hydroxide (NaOH; 1M-6M) and stirred for 20
minutes at room temperature. The solution was then adjusted
to pH 7.3 with hydrochloric acid (HCl; 1M-6M) and stirred at
room temperature for one hour. This solution was prepared
fresh before each experiment and kept on ice. Preparation of
AF64A in this manner produces 85-90% cyclization of the
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aziridinium ring (Gill and Rang l966; El Tamer et al. 1992).

surgical Procedures and Drug Treatment
The rats were anesthetized with equitensin (3ml/kg)
intraperitoneal injection, placed into a stereotaxic
apparatus

(Kopf) and their skull was exposed.

AF64A (1 nmol/1.5

~l)

was injected bilaterally, one

side at a time, into the lateral ventricles at a rate of
0.5 µl per minute. These injections were made at the
coordinates: -0.8 mm posterior, +/- l.5 mm lateral, and -3.6
mm ventral to bregma (Paxinos and Watson, 1986) . A sterile
cannula-osmotic pump assembly (Alza, Palo Alto, CA), filled
with either cytochrome C (CC; a control protein) or bFGF
(Harlan Bioproducts, Indianapolis, IN) dissolved in
artificial cerebrospinal fluid

(NaCl, 123 mM; CaC1 2 ,

0.86

mM; KCl, 3.0 mM; MgC1 2 , 0.89 mM; NaHC0 3 , 25 mM; NaH 2 P0 4 ,
mM and Na 2 HP0 4 ,

0.5

0.25 mM), was pre-equilibrated for at least

3 hours in sterile saline at 37° C. The osmotic pump was
implanted subcutaneously on the animal's back and the tip of
the cannula was stereotaxically lowered -4.0 mm ventral from
bregma into either the right or left lateral ventricle. The
cannula was affixed to the skull, via an anchoring screw,
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with dental cement (Coralite Dental Products, Skokie, Il) .
The wound was closed and the rats were administered 0.3 ml
(SO mg/ml) ampicillin subcutaneously.
AF64A treated rats received either a total of 3.24 nmol

cc

(equivalent to 40 µg and the same dose used in the other

NTF experiments) or either 0.006 or 0.011 nmol (equivalent
to 0.1 and 0.2 µg) bFGF. These doses of bFGF were chosen
because in this range, bFGF is effective in stimulating ChAT
activity and AChE staining (Potter and Morrison 1991;
Anderson et al. 1988; Araujo, Lapchak and Hefti 1993).
Cytochrome C or bFGF were administered continuously for 14
days. At the end of the treatment the rats were sacrificed
by decapitation and the brains were dissected on ice. The
hippocampus and septum were immediately placed on dry ice
and subsequently stored at -70°C.

Enzyme Assay
Tissue preparation
The hippocampus and septum were thawed in ice cold
sodium phosphate buffer 75 mM, pH 7.4,

(1 ml for hippocampal

tissue and 0.6 ml for septal tissue) and homogenized (20
sec., setting 5 on a Polytron homogenizer model# PT 10/35).
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ChAT activity
The ChAT assay followed the Fonnum method (1975). In
brief, 10 µl of tissue homogenate was added to 10 µl of
buffer substrate [cold sodium phosphate, 75 mM pH 7.4; NaCl,
600 mM; MgCl 2 ,

40 mM; eserine, 2.0 mM; bovine serum albumin,

0.05%; choline-iodide, 10 rnM; and [ 3 H]acetyl coenzyme A,
0.87 mM

(~

20 mCi/mmol)]. This mixture was then incubated

for 30 minutes at 37°C and the tubes placed on crushed ice
following incubation. One hundred and fifty µl of sodium
tetraphenylboron solution (75 mg/ml in 3-heptanone) was
added to each tube and the tubes were vortexed and
centrifuged. After centrifugation, 100 µl of the organic
(top) layer was removed and placed into scintillation vials.
Ten ml of scintillation cocktail was added and the vials
were counted using liquid scintillation spectrometry. The
level of ChAT activity was measured by subtracting the
disintegrations per minute
tissue)

(dpm)

in the blank tubes

(without

from the dpm in the tubes with tissue.

AChE activity
The AChE assay is similar to the ChAT assay but with
the following modifications

(Leventer et al. 1985). Tissue
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homogenate (10 µl) was added to 20 µl of buffer substrate
[cold sodium phosphate buffer, 75mM, pH 7.0; AChI, lOmM and
[3

H]ACh iodide 10 mM

(~

8 mCi/mmol)]. This mixture was

incubated for 20 minutes at 37°C and the tubes were then
placed into crushed ice. Ice cold water (30 µl)

was then

added to each tube followed by 150 µl sodium tetraphenylboron solution (75 mg/ml in 3-heptanone) . The tubes were
then vortexed, centrifuged, and frozen for 30 minutes at
-20°C. When removed from the freezer the organic (top)

layer

was discarded and the aqueous (bottom) layer thawed. Thirty
µl of this aqueous layer was placed into scint-illation
vials and 10 ml of scintillation cocktail was added. These
vials, along with blank tubes (assay without tissue
substrate), were counted using a liquid scintillation
spectrometer. The level of AChE activity was calculated by
subtracting the dpm in the blank tubes from the dpm in the
assay tubes with tissue.

Protein Determination
Tissue protein levels were assessed by the method of
Lowry et al.

(1951) for both the ChAT and AChE assays.
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Statistical Analysis
The levels of enzyme activity in the rats are
expressed as either nmol/mg/hr or

~

of rat treated with

AF64A/CC control. The values indicated are means ± SEM. The
data were analyzed by 'ANOVA followed by post-hoc analysis
(Fisher LSD) . The changes in the weight of the rats are
expressed as the % mean ± SEM of the rats' initial weight.
The weight data were analyzed by repeated measures ANOVA.

Results
In the hippocampus, there was no significant difference
in ChAT activity between the treatment groups (f=l.85,
p=0.181, df=2). Neither dose of bFGP 0.006 and 0.011 nmol
produced any significant change in hippocampal ChAT activity
compared with AF64A/CC treated rats (fig. 2). Septal ChAT
activity was not changed by treatment with either AF64A/CC
or AF64A/bFGF (f=2.70, p=0.0.091, df =2) (fig. 2).
Treatment with either dose of bFGF (0.006 and 0.011
nmol) after AF64A treatment did not alter hippocampal AChE
activity (f=l.452, p=0.258, df=2) (fig. 3). In the septum
there was a significant difference between the treatment
groups (f=5.72, p=0.010, df =2). The AF64A/bFGF (0.006 nmol)
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Fig. 2. ChAT activity was determined in the SHP of rats
treated with an i.c.v. injection of AF64A (1 nmol/ventricle)
and then continuously infusea with either 0.006 or 0.011
nmol bFGF for 14 days. The aata represent the mean ± SEM for
8 rats per group.
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Fig. 3. AChE activity was determined in the SHP of rats
treated with an i.c.v. injection of AF64A (1 nmol/ventricle)
and then continuously infused with either 0.006 or 0.011
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treated rats.
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The AF64A/bFGF (0.006 nmol) treated rats showed significant
(p=0.011) reduction in septal AChE compared with AF64A/CC
treated rats. AChE activity in the septum of AF64A/bFGF
(0.011 nmol) treated rats remained unchanged (fig. 3).
Rats in all treatment groups gained weight over the 14
day treatment period and there was no significant difference
between treatment groups (f=J.00, p=0.071, df=3). The
AF64A/CC, AF64A/bFGF (0.006 nmol) and AF64A/bFGF (0.011
nmol) treated rats all increased their weight in a similar
manner (28-50% increase from their initial weight) (table 1).

Discussion
In the present work, bFGF administration to AF64A
treated rats did not increase either hippocampal or septal
ChAT activity. This is in contrast with other work which has
shown that bFGF stimulates recovery of cholinergic markers
in the SHP. Studies in which cholinergic cell loss occurs
after FF transection have shown that bFGF increases
hippocampal ChAT activity (Araujo, Lapchak and Hefti 1993).
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Table 1.-- bFGF does not attenuate weight gain in AF64A
treated rats.
TREATMENT

WEIGHT-DAY 7

WEIGHT-DAY 14

AF64A/CC

110

(3.13)

132

(3.21)

AF64A/bFGF ( 0. 1)

120

(1.61)

150

(2.90)

AF64A/bFGF ( 0. 2)

113

(3.49)

128

(3.89)

Data are represented as the mean ± SEM of the % of the
rats' initial weight.
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rn rats with these lesions, bFGF administration increased
the number of septal AChE (Anderson et al. 1988) and ChAT
positive cells (Otto, Frotscher and Unsicker 1989; Araujo,
Lapchak and Hefti 1993).
Previous work with AF64A and bFGF has shown that bFGF
produces a 30% recovery in ChAT activity in the hippocampus
of AF64A treated rats (Potter and Morrison 1991) . Consistent
with the present work, Potter and Morrison (1991) also
showed that bFGF did not produce any change in the septal
ChAT activity in AF64A treated rats (Potter and Morrison
1991).
The lack of effect in the present study cannot be
accounted for by the use of an inappropriate dose of bFGF. A
dose of 0.084 µg bFGF, administered over 14 days, is
effective in stimulating cholinergic enzyme activity in
AF64A treated rats (Potter and Morrison 1991) . Other work
has shown that 0.01 µg bFGF, injected twice a week over 21
days (0.105 µg total), increased hippocampal ChAT activity
(Araujo, Lapchak and Hefti 1993) . In addition, Anderson et
al. (1988) found that 0.084

~g,

administered over 14 days,

reversed the loss of AChE staining in the septum after FF
transection. These studies indicate that the doses of bFGF
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used in the current work should have been appropriate to
alter both ChAT and AChE activity in AF64A treated rats.
In the present study, all of the animals had normal
weight gain over the 14 day treatment period and these
weight gains were comparable across treatment groups. This
is in contrast to previous work which has shown that rats
treated with bFGF after FF transection had an attenuated
weight gain over 21 days of treatment

(Araujo, Lapchak and

Hefti 1993). Further, the increased weight gain in the
present study differs from the effect of other NTFs on
weight gain (Lapchak and Hefti, 1992; Williams 1991b;
Williams and Oostveen 1992). The data in the present study
indicate that,

in AF64A treated rats, bFGF may not act like

other NTFs (see chapters 4, 5 and 6) .
A lack of growth factor infusion may have contributed
to the results of the present study. Although all of the
osmotic pumps were checked after the rats were sacrificed
and found to be empty, it is possible that since bFGF is a
larger protein than either NGF or BDNF (MW 17,500, 13,000
and 12,500 respectively) the bFGF protein adhered to the
wall of the pump and only the artificial cerebral spinal
fluid solution was pumped out.
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The lower dose of AF64A (1 nmol/ventricle) used in the
present study also may have played a role in the results.
This dose of AF64A in the AF64A/CC treated rats produced a
level of hippocampal enzyme activity of 33 nmol/mg/hour for
ChAT activity and 1875 nmol/rng/hour for AChE activity. These
levels of activity are similar to those normally found in
vehicle (water at pH 7.3) treated rats (35-42 nmol/mg/hr for
ChAT and 2000-2300 nmol/mg/hour for AChE) . Fimbria fornix
transections or treatment with 2 nmol AF64A produce
decreases in hippocampal ChAT activity of 50%-60% (Potter
and Morrison 1991; Araujo, Lapchak and Hefti 1993). A larger
change in cholinergic enzyme activity than in the present
study may be necessary for bFGF to affect cholinergic
neurons in the SHP. Whether bFGF acts on normal, nonlesioned, cholinergic neurons is unknown.
In conclusion, the present work found that bFGF did not
stimulate cholinergic enzyme activity in the SHP of AF64A
treated rats. Results of the current study indicate that a
higher dose of AF64A should be used for subsequent studies.
The lack of effect of bFGF on cholinergic neurons of the SHP
suggests that further work with this NTF in AF64A treated
rats would not be beneficial in increasing our understanding
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of the action of exogenous administration of this NTF.

CHAPTER IV
EFFECT OF NERVE GROWTH FACTOR IN NORMAL AND ETHYLCHOLINE
MUSTARD AZIRIDINIUM (AF64A) TREATED RATS: SENSITIZATION OF
CHOLINERGIC ENZYME ACTIVITY IN THE SEPTO-HIPPOC.AMPAL PATHWAY

Summary
This study examined the effects of nerve growth factor
(NGF) administration on cholinergic enzyme activity in both
normal and AF64A treated rats. Choline acetyltransferase
(ChAT) and acetylcholinesterase (AChE) activity were
measured in the hippocampus and septum of rats chronically
administered NGF (0.38-3.08 nmol) into the lateral
ventricles for 14 days. In both normal and AF64A treated
rats, NGF increased cholinergic enzyme activity in a dosedependent manner. NGF increased ChAT activity in normal rats
by 149% but, a greater effect was observed in AF64A treated
rats that had a 273% of control increase in activity. NGF
increased AChE activity in normal rats by 135% but produced
a 221% increase in this activity in AF64A-treated rats.
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Introduction
NGF is a protein involved in the development and
maintenance of neurons in both the peripheral nervous system
(PNS) and the central nervous system (CNS)

(for reviews see

Levi-Montalcini 1987; Varon et al. 1988; Korsching, 1993).
NGF acts on sympathetic and sensory neurons of the PNS as
well as on cholinergic neurons of the basal f orebrain in the
CNS (Longo et al. 1993; Ayer-Lelievre 1983; Varon et al.,
1989) . In the basal forebrain, NGF mRNA and NGF receptors
have been localized in the septo-hippocampal pathway (SHP)
(Lindsay et al. 1994; Cuello, Maysinger, and Garofalo

1992;

Lauterborn et al. 1994a; Senut et al. 1990). In this
pathway, immunoreactivity for NGF and its receptors have
been co-localized with neurons expressing cholinergic
phenotypic markers (Woolf, Gould and Butcher 1989; Liberini
and Cuello 1994; Rylett and Williams, 1994). This evidence
and supporting data demonstrate the retrograde transport of
NGF (Ferguson et al. 1991; Korsching 1986; Liberini and
Cuello 1994) and have established NGF as a key neurotrophic
factor in the SHP.
Transection of the PF, the major septal cholinergic
pathway to the hippocampus (Amaral and Kurz 1985), causes a
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reduction in cholinergic phenotypic markers such as ChAT
immunoreactivity, AChE staining and ChAT activity in the SHP
(Armstrong et al. 1987; Tuszynski et al. 1990). In vivo
administration of NGF has been shown to reverse cholinergic
deficits found after FF transection (Gage et al. 1988; Hagg
et al. 1988; Hagg et al. 1989; Kromer 1987; Montero and
Hefti 1988; Svendsen, Cooper and Sofroniew 1991).
Although work in rats with FF transections indicate
that NGF treatment can produce changes in cholinergic
markers, studies assessing the action of NGF in normal,
unablated rats have not been as clear. Several studies have
indicated that the effect of NGF on cholinergic markers in
the SHP is dependent on damage or cholinergic deficiencies
in this pathway (Gage et al. 1988; Hefti et al. 1984;
Schinstine and Cornbrooks 1989; Williams, Jodelis and Donald
1989; Garofalo, Ribeiro-Da-Silva and Cuello 1992). Other
studies indicate that NGF administration to rats with an
intact SHP can increase cholinergic phenotypic markers in
the medial septum and hippocampus (Fusco et al. 1989;
Vantini et al. 1988).
A direct comparison between the effects of NGF on
septal cholinergic neurons in normal rats and rats with
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decreased cholinergic phenotypic markers has not been done.
Further, much of the work involving NGF administration in FF
transected rats has focused on the effects seen at the cell
bodies located in the medial septum. A more complete
analysis of the action of NGF on the entire SHP (the cell
body and terminal region)

is necessary in order to determine

the interaction of these two regions when rats with and
without reduced cholinergic phenotypic markers are treated
with NGF.
AF64A is a neurotoxin which has been previously shown
to be selective in a dose-dependent manner for cholinergic
neurons in the SHP (Chrobak et al. 1988; Fisher et al. 1982;
Hortnagl et al. 1987a,b). When administered into the lateral
ventricle AF64A reduces ChAT and AChE activity in the
hippocampus (Chrobak et al. 1987; Calhoun et al. 1986; El
Tamer et al. 1992; Hanin 1990) as well as high affinity
choline transport (HAChT), acetylcholine (ACh), and ChAT
immune-reactivity in the SHP (El Tamer et al. 1992; Fisher
et al. 1982; Leventer et al. 1985; Lorens et al. 1991).
Accordingly, AF64A provides a means to produce cholinergic
deficits in the SHP without the gross anatomical disruption
seen when the FF is transected.
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The present study compared the effects of NGF
administration on SHP neurons in AF64A-treated rats with its
effects on normal, non-AF64A treated rats. Whether AF64A
treated rats were more sensitive to chronic treatment with
NGF and whether this sensitivity was dose dependent was
evaluated. NGF was found to increase cholinergic enzyme
activity in the SHP of both the AF64A treated and nontreated rats, in a dose dependent manner. Further, AF64A
treated rats were more sensitive to the effects of NGF on
cholinergic enzyme activity.

Materials and Methods
Animals
Adult, male Sprague-Dawley rats (Zivic Miller
Laboratories, Allison Park, PA.) weighing between 230-392
grams were used. They were housed two per cage in a room on
a 12 hour light cycle and had access to food and water g.d
libitum. A total of 126 rats were used in this study. The
rats were weighed at the time of surgery as well as 7 and 14
days post surgery. These rats were used under the auspices
of the IACUC.
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AF64A
AF64A was prepared according to standard methods
(Fisher et al. 1982). Briefly, acetyl ethylcholine mustard
hydrochloride (UCB, Belgium) was dissolved in water to a
concentration of 1 mM. This solution was adjusted to pH 11.5
with sodium hydroxide (NaOH; 1M-6M) and stirred for 20
minutes at room temperature. The solution was adjusted to pH
7.3 with hydrochloric acid (HCl; lM-6M) and stirred at room
temperature for one hour. This solution was prepared fresh
before each experiment and kept on ice. Preparation of AF64A
in this manner produces 85-90% cyclization of the
aziridinium ring (Gill and Rang 1966; El Tamer et al. 1992).

Surgical Procedures and Drug Treatment
Rats were anesthetized with intraperitoneal injections
of equitensin (3ml/kg), placed into a stereotaxic apparatus
(Kopf) and their skull was exposed.
In the NGF dose-response experiment in normal rats, the
rats were sham operated by having two needles (26 gauge)
lowered into the lateral ventricles through two holes
drilled at the coordinates of: -0.8 mm posterior, +/- 1.5 mm
lateral, and -4.0 mm ventral to bregma (Paxinos and Watson

75

1986) . The needles were left in place for one minute and
then removed. A sterile cannula-osmotic pump assembly (Alza,
Palo Alto, CA), filled with either cytochrome C (CC; a
control protein) (40 µg; 3.24 nmol) or NGF (5-40 µg;

0.38-

3.08 nmol total) (Harlan Bioproducts, Indianapolis, IN)
dissolved in artificial cerebrospinal fluid (NaCl, 123 mM;
CaC1 2 ,
NaH 2 P0 4 ,

0.86 mM; KCl, 3.0 mM; MgC1 2 ,
0.5 mM and Na 2 HP0 4 ,

0.89 mM; NaHC0 3 ,

25 mM;

0.25 mM) containing 1% bovine

serum albumin was pre-equilibrated for at least three hours
in sterile saline at 37°C. The osmotic pump was implanted
subcutaneously on the animal's back and the tip of the
cannula was stereotaxically lowered into either the right or
left lateral ventricle. The cannula was affixed to the
skull, via an anchoring screw, with dental cement

(Coralite

Dental Products, Skokie, Il). The wound was closed and the
rats were administered 0.3 ml

(50 mg/ml) ampicillin

subcutaneously. One of the 40 rats in this experiment died
prior to completion.
In the dose-response experiments with AF64A treated
rats, the control rats (VEH/CC) had water at pH 7.3 as
vehicle (VEH)

injected into the lateral ventricles (see

coordinates given above) . Rats in the AF64A treatment groups
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had

AF64A (1.5 nmol) injected into their lateral

ventricles. These injections were bilateral, one side
injected at a time, at a rate of 0.5 µl per minute. The
cannula-pump assembly was implanted as described for the
normal rats. In this experiment 48 rats were used of which 3
were eliminated due to surgical difficulties and one died.
In both dose-response experiments, CC or NGF (5-40 µg;
0.38-3.08 nmol total) was administered continuously for 14
days. The doses of NGF were determined from previous work
which has shown that administration of 16.8, 40 or 80 µg NGF
to FF transected rats increases cholinergic phenotypic
markers in the SHP (Hefti, Dravid and Hartikka 1984; Montero
and Hefti 1988; Williams, Jodelis and Donald 1989). At the
end of the treatment the rats were sacrificed by
decapitation and the brains were dissected on ice. The
tissue samples (hippocampus, septum and striatum) were
immediately placed on dry ice and subsequently stored at 70°c.

In a third experiment directly comparing the effects of
NGF in VEH and AF64A treated rats, either VEH (water, pH
7.3) or AF64A (1.5 nmol) were administered bilaterally into
the lateral ventricles. Post injection, the rats were
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implanted with a cannula-pump assembly containing either

cc

or NGF (3.08 nmol) as described previously in this

dissertation. Therefore, this experiment had four treatment
groups: VEH/CC, AF64A/CC, AF64A/NGF and VEH/NGF. An
additional group, which corresponded to the controls in the
dose-response study in normal rats, was sham operated and
then administered CC. The rats were treated for 14 days and
then the hippocampus, septum, and striatum were collected. A
total of 38 rats were used in this experiment (14 in the
control group and six to eight in all other treatment
groups). Of these 38 rats, one was eliminated from the
analysis due to post-surgical complications and one rat died
during the experiment.

Enzyme Assays
Tissue preparation
All tissue samples (hippocampus, septum, and striatum)
were thawed in ice cold sodium phosphate buffer 75 mM, pH
7.4,

(1 ml for hippocampal tissue, 0.6 ml for septal tissue

and 2 ml for striatal tissue) and homogenized (20 sec. @
setting 5 on a Polytron homogenizer model # PT 10/35). For
the septal and hippocampal samples, the tissue homogenate
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was then divided into two aliquots, one for the ChAT and
AChE assays and the other for the GAD assay. The ChAT/AChE
homogenate was frozen at -70°C until the assays were
conducted. To the GAD homogenate,

0.1% Triton XlOO and 2.5

mM aminoethylisothiouronium bromide in 100 mM potassium
phosphate buffer (pH 7.2) was added.

ChAT activity
The ChAT assay followed the Ponnum method (1975) . In
brief, 10 µl of tissue homogenate was added to 10 µl of
buffer substrate {cold sodium phosphate, 75 mM pH 7.4; NaCl,
600 mM; MgC1 2 ,

40 mM; eserine, 2.0 mM; bovine serum albumin,

0.05%; choline iodide, 10 mM; and [ 3 H]acetyl coenzyme A,
0.87 mM (= 20 mCi/mmol)}. This mixture was then incubated
for 30 minutes at 37°C and the tubes placed on crushed ice
following incubation. One hundred and fifty µl of sodium
tetraphenylboron solution (75 mg/ml in 3-heptanone) was
added to each tube and the tubes were vortexed and
centrifuged. After centrifugation, 100 µl of the organic
(top)

layer was removed and placed into scintillation vials.

Ten ml of scintillation cocktail was added and the vials
were counted using liquid scintillation spectrometry. The
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level of ChAT activity was measured by subtracting the
disintegrations per minute (dpm)
tissue)

in the blank tubes (without

from the dpm in the tubes with tissue.

AChE activity
The AChE assay is similar to the ChAT assay, but with
the following modifications (Leventer et al. 1985). Tissue
homogenate (10 µl)

was added to 20 µl of buffer substrate

[cold sodium phosphate buffer, 75m.M, pH 7.0; AChI, lOmM and
[

3

H]ACh iodide 10 mM

(=

8 mCi/mmol)]. This mixture was

incubated for 20 minutes at

37~c

and the tubes were then

placed into crushed ice. Ice cold water (30 µl) was then
added to each tube followed by 150 µl sodium
tetraphenylboron solution (75 mg/ml in 3-heptanone). The
tubes were then vortexed, centrifuged, and frozen for 30
minutes at -20°c. When removed from the freezer the organic
(top) layer was discarded and the aqueous

(bottom) layer

thawed. Thirty µl of this aqueous layer was placed into
scintillation vials and 10 ml of scintillation cocktail was
added. These vials, along with blank tubes (assay without
tissue substrate), were counted using a liquid scintillation
spectrometer. The level of AChE activity was calculated by
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subtracting the dpm in the blank tubes from the dpm in the
assay tubes with tissue.

GAD activity
Glutamic acid decarboxylase activity was determined by
(3

H]GABA formation and cation exchange isolation (Maderdrut

1979). Twenty microliters of tissue homogenate was added to
30 µl of buffer substrate containing: 500 µM EDTA tetrasodium salt hydrate, 200

~M

pyridoxal-5'-phosphate, 12 mM

glutamic acid and 10 mM GABA in potassium phosphate buffer
(pH 7.2, 100 mM). This solution was spiked with [ 3 H]
glutamic acid for a specific activity of 0.27 µCi per assay.
The blanks, used to define non-specific activity, consisted
of tubes containing 20 µl of buff er substituted for the
tissue homogenate. The samples were incubated for 30 minutes
at 37°C and then placed on ice while 500 µl of 5%

trichlo-

roacetic acid was added before the tubes were vortexed. The
samples were loaded into column containing 4 cm of 50W-X4
cation exchange resin (Bio-Rad Laboratories, Melville, N.Y.)
which had been equilibrated with 4 ml of 2N NaOH followed by
5 ml of 0.2M citric acid. In order to remove any nonspecific bound [ 3 H] glutamic acid, the columns were washed
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with 9 ml of sodium citrate buffer (0.2M, pH 3.5) and then
[3

H] GABA was eluted by the addition of 4 ml of cold sodium

acetate (0.2M, pH 5.5) to the column. The eluate was
collected into scintillation vials and 12 ml of scintillation cocktail was added. The vials were counted and the
amount of specific activity was determined by subtracting
the dpm in the blanks from those in the samples.

Protein Determination
Tissue protein levels were assessed by the method of
Lowry et al. (1951)

for both the ChAT and AChE assays.

Statistical Analysis
The level of enzyme activity in the rats are expressed
as either nmol/mg/hr or % control. The values indicated are
means ± SEM. The data were analyzed by ANOVA followed by
post-hoc analysis (Fisher LSD) . Changes in the weight of the
rats are expressed as the

~

mean ± SEM of the rats' initial

weight and these data were analyzed by repeated measures
ANOVA.
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Results
Cholinergic Enzyme Activity in Normal Rats
In normal rats, 14 day administration of NGF changed
cholinergic enzyme activity in both the hippocampal and
septal regions. NGF produced a significant (f=6.99, p=0.000,
df=4)

increase in ChAT activity in the hippocampus (fig. 4).

This increase was dose-dependent since the level of enzyme
activity in rats treated with 3.08 nmol NGF was significantly greater (142% of control) than that in rats treated
with 0.38 nmol NGF

(130~

of control, p=0.017). The septal

region also showed a significant increase in the level of
ChAT activity (f=4.87, p=0.003, df=4) with the highest being
149% of control for the dose of 3.08 nmol NGF (fig. 4).
Hippocampal and septal AChE activity remained unchanged
after NGF treatment (f=0.55, p=D.703, df=4 and f=0.87,
p=0.491, df=4 respectively; fig. 5).
GAD activity in the hippocampus remained unchanged by
NGF treatment (f=0.91, p=0.472, df=4; fig. 6). In the
septum, there was a significant alteration in GAD activity
(f=2.93, p=0.035, df=4). This significance is attributed to
changes in the level of GAD activity across the doses of NGF
(p< 0.05, 0.38 nmol verses 0.77, 1.54 and 3.08 nmol NGF).
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Fig. 4. ChAT activity in the hippocampus and septum of
normal rats treated for 14 days with either CC (40 µg, 3.24
nmol) or NGF (5-40 µg, 0.38-3.08 nmol). There were 7-8 rats
per treatment group. ~, p< 0.05 compared with CC treated
rats and a, p< 0.05 compared with 0.38 nmol NGF.
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nmol) or NGF (5-40 µg, 0.38-3.08 nmol). There were 7-8 rats
per treatment group.
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None of the NGF treated rats had levels of GAD activity
significantly different (p >0.05) from rats treated with CC.
In the striatal tissue, NGF produced an increase of
both ChAT and AChE activity. ChAT activity in this tissue
was significantly increased (f=l9.60, p=0.000, df=4). The
doses of 0.38 and 3.08 nrnol NGF increased ChAT activity 123%
and 170% of control respectively (fig. 7). AChE activity in
the striatum was also significantly increased (f=3.41,
p=0.019, df=4). This increase only occurred at the highest
dose of NGF ( 3. 0 8 nmol) (fig. B) . The increase in both of
these enzymes was dose-dependent since the highest dose of
NGF (3.08 nmol)

induced a larger increase in enzyme activity

than the lowest dose (0. 38 nrnol) (p< 0. 05).

Changes in Cholinergic Enzyme Activity in AF64A Treated Rats
In the dose-response experiment with AF64A treated
rats, hippocampal ChAT activity was unchanged (f=l.30,
p=0.284, df=5). Rats treated with AF64A/CC had a 28%, nonsignificant, reduction in ChAT activity from control values
(fig. 9). AF64A/NGF treated rats did not have any changes in
the level of hippocampal ChAT activity compared with control
rats (fig. 9).
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ChAT activity in the striatum of normal rats
treated for 14 days with either CC (40 µg, 3.24 nmol) or NGF
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Fig. 9. ChAT activity in the SHP of AF64A/NGF treated rats.
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol)
continuously for 14 days. Each treatment group consisted of
7-8 rats. *, p< 0.05 compared with VEH/CC treated rats; **,
p< 0.05 compared with AF64A/CC treated rats and a, p< 0.05
compared with AF64A/NGF 0.38 nmol.
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AF64A/NGF treated rats showed a robust increase
(f=l0.39, p=0.000, df=5)

in septal ChAT activity at all

doses of NGF administered. ChAT activity increased up to
273% of control in rats administered 1.54 nmol of NGF. This
increase was significantly (p=0.018) greater compared with
rats administered 0.38 nmol NGF and indicates that NGF
stimulation of ChAT activity in AF64A treated rats is dosedependent (fig. 9). AF64A/CC treated rats did not show a
significant increase in enzyme activity.
In the hippocampus, AChE activity was unaltered by
AF64A/NGF treatment (0.38-3.08 nmol NGF) (f=0.90 p=0.489,
df=5; fig. 10). AF64A/CC treated rats had a non-significant
decrease (23% of control) of hippocampal AChE activity.
Septal AChE activity was significantly changed (f=6.61,
p=0.000, df=5) but, was less responsive to AF64A/NGF
treatment than ChAT activity. AChE activity was significantly increased (p< 0.01)

171~

and 221% of control for the

doses of 0.38 and 1.54 nmol NGF respectively (fig. 10)
These increases were dose-dependent since there was a
significant difference (p=0.047) between the level of
activity in rats treated with 0.38 nmol and 1.54 nmol NGF.
AF64A/CC and AF64A/NGF treated rats showed no change in
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Fig. 10. AChE activity in the SHP of AF64A/NGF treated rats.
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol)
continuously for 14 days. Each treatment group consisted of
7-8 rats. *, p< 0.05 comparea with VEH/CC treated rats; **,
p< 0.05 compared with AF64A/CC treatea rats and a, p< 0.05
compared with AF64A/NGF 0.38 nmol.
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GAD activity in either the hippocampus or septum (f=l.084,
p=0.38, df=5 and f=l.88, p=0.121, df=5 respectively; fig.
11) .
In striatal tissue, AF64A/CC treatment did not produce
any significant change in ChAT activity compared with VEH/CC
treated rats. AF64A/NGF treated rats, in contrast, showed a
dose-dependent increase in ChAT activity (f=20.02, p=0.000,
df=5). ChAT activity increased (p< 0.01) to 128% and 151% of
VEH/CC respectively, for the 0.38 nmol and 3.08 nmol doses
of NGF (fig. 12) and the level of enzyme activity at these
doses were significantly different (p=0.01) from each other.
AChE activity was unchanged in both the AF64A/CC and
AF64A/NGF treated rats (f=0.70, p=0.624, df=5; fig. 13).

Direct Comparison of the Effects of NGF in VEH and AF64A
Treated Rats
In the third experiment directly comparing NGF's affect
in VEH and AF64A treated rats, sham operated and VEH/CC
treated rats showed similar levels of enzyme activity in
both the hippocampus and septum for ChAT, AChE, and GAD
activity (p >0.05 by independent t-test). These two treatments were grouped together into one control group (CONT) .
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Fig. 11. GAD activity in the BHP of AF64A/NGF treated rats.
VEH (water at pH 7.3) or AF6qA (1.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol)
continuously for 14 days. Each treatment group consisted of
7-8 rats.
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Fig. 12. ChAT activity in the striatum of AF64A/NGF treated
rats. VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle)
was administered by i.c.v. injection. Rats were then infused
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol)
continuously for 14 days. Each treatment group consisted of
7-8 rats. *, p< 0.05 compared with VEH/CC treated rats; **,
p< 0.05 compared with AF64A/CC treated rats and a, p< 0.05
compared with AF64A/NGF 0.38 nmol.
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Fig. 13. AChE activity in the striatum of AF64A/NGF treated
rats. VEH (water at pH 7.3) or AF64A (l.5 nmol/ventricle)
was administered by i.c.v. injection. Rats were then infused
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol)
continuously for 14 days. Each treatment group consisted of
7-8 rats.
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In the hippocampus, the level of ChAT activity was
significantly altered between treatment groups (f=l0.19,
p=0.000, df=3). AF64A/CC produced a significant (p=0.007),
27%, reduction in ChAT activity compared with VEH/CC treated
rats. Rats treated with AF64A/NGF had only a 10% reduction
in enzyme activity and this was not significantly different
from either VEH/CC or AF64A/CC treated rats

(p >0.05).

VEH/NGF treated rats increased (p=0.003) their ChAT activity
to 127% of control (fig. 14). In this experiment, ChAT
activity changed significantly (f=36.82, p=0.000, df=3)

in

the septum. Septal ChAT activity was not changed by AF64A/CC
but, was significantly (p=0.000) increased in both the
AF64A/NGF and VEH/NGF treated rats by 211% and 148% of
control, respectively. Although both the AF64A/NGF and
VEH/NGF treated rats had increased septal ChAT activity, the
level of ChAT activity was significantly (p=0.000) different
between these two groups (fig. 14).
In this third experiment, AChB activity significantly
differed between treatment groups in both the hippocampus
(f=ll.29, p=0.000, df=3) and septum (f=20.04, p=0.000,
df=3). AChE activity in the hippocampus was significantly
(p=0.000) decreased by 31% following AF64A/CC treatment

102

240
220

SEPTUM
HIPPOCAMPUS

200
~
~

ii-I

~
~

160

i..

.c

u e
< :::::.
~ e
._,

bl)

Q

<
..= =

u

*
**

180

--

#

140
120
100
80
60
40
20
CONT

AF64A!

cc

AF64A/
NGF

VEH/
NGF

TREATMENT
Fig. 14. Comparison of the effect of NGF in VEH and AF64A
treated rats. Rats were treated with either CC or NGF for 14
days. The control group (CONT) is composed of rats which
were treated with CC alone or VEH/CC (see text for details).
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
continuously for 14 days with either CC (3.24 nmol) or NGF
(3.08 nmol). There were 14 rats in the control group and 6-8
in all other groups. *, p< 0.05 compared with CONT treated
rats; **, p< 0.05 compared with AF64A/CC treated rats and#,
P< 0.05 compared with VEH/NGF.
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compared with the activity in VEH/CC treated rats. AChE
activity in AF64A/NGF treated rats was also significantly
(p=0.000) decreased compared with VEH/CC treated rats. In
contrast to the ChAT activity in these rats, the VEH/NGF
treated rats did not exhibit a significant change in
hippocampal AChE activity. Septal AChE activity was not
changed in rats treated with AF64A/CC. AF64A/NGF and VEH/NGF
treatment produced a 189% and 135% of control increase in
septal AChE activity respectively (p< 0.01) (fig. 15). This
increase in AChE activity was significantly (p=0.000)
different between these two treatment groups.
All three treatment groups (AF64A/CC, AF64A/NGF, and
VEH/NGF) showed no change in GAD activity in either the
hippocampus or septum (f=0.60, p=D.619, df=3 and f=0.40,
p=0.756, df=3 respectively; fig. 16).
Striatal ChAT activity was altered by the various
treatment groups in this experiment (f=43.76, p=0.000, df=3)
ChAT activity in striatal tissue was not changed by AF64A/CC
but, was increased (p< 0.01) by both AF64A/NGF and VEH/NGF
treatment (171% and 158% of control respectively; Fig. 17).
These increases in enzyme activity were not different
between the two treatment groups (p=0.13).
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Fig. 15. Comparison of the effect of NGF in VEH and AF64A
treated rats. Rats were treated with either CC or NGF for 14
days. The control group (CONT) is composed of rats which
were treated with CC alone or VER/CC (see text for details).
VEH (water at pH 7.3) or AF64A (l.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
continuously for 14 days with either CC (3.24 nmol) or NGF
(3.08 nmol). There were 14 rats in the control group and 6-8
in all other groups. *, p< 0.05 compared with CONT treated
rats; **, p< 0.05 compared with AP64A/CC treated rats and#,
P< 0.05 compared with VEH/NGP.
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Fig. 16.
Comparison of the effect of NGF in VEH and AF64A
treated rats. Rats were treatea with either CC or NGF for 14
days. The control group (CONT) is composed of rats which
were treated with CC alone or VEH/CC (see text for details) .
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
continuously for 14 days with either CC (3.24 nmol) or NGF
(3.08 nmol). There were 14 rats in the control group and 6-8
in all other groups.
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Fig. 17. Comparison of the effect of NGF in the striatum of
VEH and AF64A treated rats. Rats were treated with either CC
or NGF for 14 days. The control group (CONT) is composed of
rats which were treated with CC alone or VEH/CC (see text
for details). VEH (water at pH 7.3) or AF64A (1.5 nmol/
ventricle) was administered by i.c.v. injection. Rats were
then infused continuously for 14 days with either CC (3.24
nmol) or NGF (3.08 nmol). There were 14 rats in the control
group and 6-8 in all other groups. *, p< 0.05 compared with
CONT treated rats and**, p< 0.05 compared with AF64A/CC
treated rats.
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AChE activity in the striaturn showed no change (f=l.18,
p=0.331, df=3) after AF64A/CC, AF64A/NGF or VEH/NGF
treatment compared with control treated rats (fig. 18).

Effect of NGF on Weight Gain in Normal and AF64A Treated
Rats
The weights of all rats were measured. Table 2
indicates that normal rats treated with NGF gained
significantly less weight (8%-24%) than those treated with
CC (32%) (f=S.95, p=0.001, df=4) after 14 days of treatment.
In the AF64A/NGF dose response experiment, there was a
significant difference in weight gain between treatment
groups (f=7.38, p=0.000, df=S). AF64A/CC treated rats had
weight gain similar to VEH/CC treated rats over the 14 day
treatment period (table 3). Rats treated with AF64A/NGF had
a marked attenuation in weight gain (only a 3-8% increase
from their initial weight). All the AF64A/NGF treated rats,
regardless of the dose of NGF administered, showed a
significant difference in weight at the end of the 14 day
treatment compared with either VEH/CC or AF64A/CC treated
rats (p< 0.01).
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Fig. 18. Comparison of the effect of NGF in VER and AF64A
treated rats. Rats were treated with either CC or NGF for 14
days. The control group (CONT) is composed of rats which
were treated with CC alone or VEH/CC (see text for details) .
VER (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was
administered by i.c.v. injection. Rats were then infused
continuously for 14 days with either CC (3.24 nmol) or NGF
(3.08 nmol). There were 14 rats in the control group and 6-8
in all other groups.
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Table 2.-- Changes in the weight of normal rats
treated with NGF over 14 days.
TREATMENT

WEIGHT ON DAY 7

WEIGHT ON DAY 14

cc

111 (3. 82)

142

( 1. 13)

0.38 nmol

110 (3. 3 6)

138

( 3. 63)

0.77 nmol

103 (6. 56)

126 (6.58)*

1. 54 nmol

111 (3. 47)

124

3.08 nmol

109 (3. 2 6)

115 (4.06)*

(6.71)*

Data are expressed as the % mean ± SEM of the rats'
initial weight on day 1 which was 100% (100% for CC
on day 1 was 257 g). *, p< 0.05 compared with CC (3.24 nmol)
treated rats.

Table 3.-- Changes in the weight of AP64A/NGF treated rats.
TREATMENT

WEIGHT ON DAY 7

WEIGHT ON DAY 14

VEH/CC

111 (3 - 6 5)

132 (3.85)

AF64A/CC

110 (2.65)

132 (2.87)

AF64A/0.38 nmol

109 (2.20)

108 (3.38)**

AF64A/0.77 nmol

104 (1.94)'"'

108 (5.69)**

AF64A/1.54 nmol

100 (4.62)'"'

103 (6.47)**

AF64A/3.08 nmol

102 (5 - 71)

106 (5.50)**

Data are expressed as the ~ mean ± SEM of the rats'
initial weight on day 1 which was 100% (100% for VEH/CC
on day 1 was 309 g). AF64A was administered i.c.v. at a dose
of 1.5 nmol per ventricle. '"', p< 0.05; **, p < 0.01 compared
with VEH/CC treated rats.
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Similar to the dose-response experiments, AF64A/NGF
treated rats in the direct comparison experiment also had an
attenuation in weight gain compared with the control group
(table 4) at days 7 and 14 (p=0.01 and 0.003). The VEH/NGF
treated rats in this experiment showed a slight decrease in
weight gain compared with the control group.

Discussion
The present study evaluated the action of several doses
of NGF on cholinergic neurons of the SHP in normal rats as
well as those treated with AF64A.
Previous work investigating the action of NGF on
cholinergic neurons in normal rats has been conflicting. NGF
has been shown not change ChAT activity in normal rats while
reversing decreases in enzyme activity induced by FF
transection (Williams, Jodelis and Donald 1989; Hefti et al.
1984) . In addition, ChAT imrnunoreactivity is not changed in
normal rats treated with NGP (Gage et al. 1988).
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Table 4.-- Changes in the weight of rats used in the direct
comparison study.
TREATMENT

WEIGHT ON DAY 7

WEIGHT ON DAY 14

Control

106 (0.71)

124 (1.64)

AF64A/CC

109 (3.27)

125 (4.10)

AF64A/NGF
VEH/NGF

98

(0.48)~*"

102 ( 1. 08)

109 (2.65)**
118 (1.48)

Data are expressed as the % mean ± SEM of the rats'
initial weight on day 1 which was 100~ (100% for CC
on day 1 was 356 g). AF64A was administered i.c.v.
at a dose of 1.5 nmol per ventricle. **, p< 0.01 compared with control rats.
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In contrast to these findings, several studies have shown
that NGF administered to normal rats stimulates ChAT
activity in both the septum and hippocampus (Vahlsing et al.
1991; Rylett and Williams 1994; Fusco et al. 1989; Vantini
et al. 1988; Williams 199la).
The results of the current study concur with findings
that normal, non-compromised cholinergic neurons of the SHP
are responsive to exogenously administered NGF. Further, the
action of NGF occurred in a dose-dependent manner. NGF
administration clearly affected ChAT activity in normal rats
while AChE activity did not change in NGF treated rats.
These results are supported by previous studies showing that
NGF administration to rats whose PF was unablated did not
produce a change in AChE activity (Fusco et al. 1989; Hefti
et al. 1984). These data indicate that NGF interacts with
mature cholinergic neurons of normal adult rats.
The current study indicates that high doses of NGF does
not stimulate hippocampal cholinergic enzyme activity in
AF64A treated rats. These data are in agreement with
previous in vivo work which demonstrated that NGF
administration, to AF64A treated rats, did not affect AF64A
induced decreases in cholinergic phenotypic markers (Johnson
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et al. 1988; Potter and Morrison 1991). In vitro, NGF has
also been shown to reverse AF64A induced decreases of ChAT
activity in rat brain reaggregate cultures (Atterwill and
Meakin 1990). The current study, in conjunction with the
current literature, indicate that NGFs action in vivo on the
cholinergic terminals (hippocampal region) of AF64A treated
rats is minimal.
NGF did not alter AChE activity in the hippocampus of
AF64A treated rats. AF64A/NGF treated rats had changes in
septal AChE activity similar to the changes seen in ChAT
activity of these animals. Although the pattern of response
to NGF was similar, the increase in AChE activity was less
(221% compared with 273% for ChAT) . This data indicates that
the increases in both ChAT and AChE activity in the septum
of AF64A/NGF treated are in contrast to NGFs action in
normal rats where NGF only alters ChAT activity.
In the present work, enzyme activity in GABAergic
neurons was not altered by NGF administration to either
normal or AF64A treated rats and suggests that NGF is
selective for cholinergic neurons in the SHP. Previous work
demonstrated that NGF administration did not alter FF
transection induced changes in GAD-IR (Montero and Hefti
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1988). In rats with cortical lesions, GAD activity in the
SHP after i.c.v. infusion of NGF was also unaltered
(Garofalo and Cuello 1994). The current study extended these
results by administering NGF over a range of doses and
found that, over this range

(0.38-3.08 nmol), NGF did not

alter GAD activity in the SHP. Further, the present work
concurs with previous studies showing that AF64A does not
alter hippocampal GAD activity (Reine et al. 1992; Calhoun,
Myles, and Rylett 1986).
The present study demonstrates that an interaction
occurs in the SHP between the terminal and cell body of
these neurons. Rats treated with AF64A/NGF demonstrated
increases in both ChAT and AChE activity to levels of 273%
and 221% of control, respectively. In contrast, normal rats
treated with NGF had increases in their enzyme activities of
149% for ChAT and 135% for AChE. Other studies have also
found that rats with deficits in cholinergic phenotypic
markers have increased sensitivity to NGF administration
(Williams et al. 1989; Williams 1991a; Yunshao et al. 1992)
Together with the current study, this indicates that when
cholinergic neurons of the SEP are compromised, these
neurons have an increased sensitivity to the effects of
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exogenously administered NGF compared with neurons that are
not compromised. The increased responsiveness of AF64A
treated rats to NGF indicates that the action of this toxin
at neuronal terminals (decrease of cholinergic enzyme
activity in the hippocarnpus) affects the activity which
occurs in the cell body (increased responsiveness to NGF in
the septum) . The present work therefore provides a good
model of neuronal integration by demonstrating the
relationship between changes that occur in the hippocampus
and septum.
One possible explanation for the increased
responsiveness of AF64A treated rats to NGF is that AF64A
may increase the level of endogenous NGF in the SHP. Other
noxious insults to the BHP such as lesions (Weskamp et al.
1986; Lauterborn et al. 1994b; Scott et al. 1994; Lindvall
et al. 1994; Conner et al. 1994i and Gall and Isackson
1989); electrical stimulation (Ernfors et al. 1991); or
kainic acid administration (Gall et al. 1991), have been
shown to produce an increase in NGF, its mRNA and its
receptors. An increase in endogenous NGF would result in a
higher level of NGF available to the BHP cholinergic neurons
of AF64A/NGF treated rats compared with that found in rats
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treated with NGF alone.
Another explanation could be that AF64A inhibits axonal
transport. Previous work has shown that in both the CNS and
PNS, AF64A, at high doses, inhibits axonal transport (Kasa
and Hanin 1985) . If axonal transport is blocked by AF64A,
one would expect an accumulation of the enzyme protein in
the septum and a deficit in the hippocampus. This
corresponds to the data in the present study in which AF64A
treated rats had a robust increase in enzyme activity in the
septum and no change in the hippocampus. In normals rats,
changes (increase) in enzyme activity produced by NGF was
evenly distributed in the SHP, as would be expected if
axonal transport was functioning properly.
The present work showed that cholinergic enzyme
activity in the striatum was not altered by i.c.v.
administration of 1.5 nmol AF64A. This is in agreement with
work that has shown that i.c.v. injections of 2-3 nmol AF64A
does not alter ACh levels (Potter et al. 1989) or ChAT and
AChE activity (Leventer et al. 1985) in the striatum. In
contrast, intrastriatal injection of 0.4 nmol AF64A produced
a reduction in ChAT and AChE activity in the striatum
(McGurk et al. 1987).
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The current study indicates that ChAT activity in the
striatum is responsive to NGP in a dose-dependent manner.
Changes in cholinergic neuronal activity in the striatum
after NGF administration have been reported previously.
Several groups have demonstrated that i.c.v. administration
of NGF increases cell body size (Vahlsing et al. 1991) and
ChAT activity (Altar et al. 1992; Williams and Oostveen
1992) . In the present study, the action of NGF on
cholinergic enzyme activity in the striatum was confirmed
and it was further demonstrated that this action was dosedependent. In addition, in this brain region, NGF increased
enzyme activity in a similar manner to both AF64A/NGF and
VEH/NGF treated rats indicating that the increased response
to NGF in the septum of AP64A/NGF treated rats is AF64Adependent.
Similar to previous work (Lapchak and Hefti, 1992;
Williams 199lb; Williams and Oostveen 1992), NGF treated
rats in the current study had an attenuation in normal
weight gain compared with non-NGF treated rats. This lack of
weight gain may be due to a decrease in food consumption
(Williams 199lb). Similar to the sensitization that occurred
in cholinergic enzyme activity of AF64A/NGF treated rats,
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these rats were also more sensitive to the effects that NGF
had on weight gain. Further, the AF64A/NGF group (1.54 nmol
NGF) which had the least amount of weight gain, had the
greatest increase in septal enzyme activity. These data
further support the possibility that AF64A induces an
increase in endogenous NGF. Such an increase, coupled with
exogenously administered NGF, should result in less weight
gain in AF64A treated rats than in normal rats treated with
NGF.
In conclusion, NGF administration to both normal and
AF64A treated rats produced an increase in cholinergic
enzyme activity. Furthermore, AF64A treated rats have an
increased sensitivity to the effects of NGF on cholinergic
neurons in the SHP. These findings raise the possibility
that degenerating neurons in SDAT patients might also be
more sensitive to NGF.

CHAPTER V
TEMPORAL ACTION OF NGF IN THE SBP OF NORMAL AND AF64A
TREATED RATS, IN VIVO

Summary
When administered into the lateral ventricles, NGF
increases cholinergic enzyme activity and expression in the
SHP. This increase in enzyme activity occurs in both normal
rats as well as those with decreased cholinergic phenotypic
markers. NGF administration to normal rats over 14 days
produces an increase in ChAT activity in the septum and
hippocampus (Fusco et al. 1989). NGF's action on cholinergic
enzyme activity in normal rats, when administered over
shorter periods of time, has not been previously reported.
In the present study, NGF was administered for 3 thru 28
days to normal rats, as well as those treated with the
neurotoxin, AF64A. AF64A/NGF treated rats had an increase of
179% of control in septal ChAT activity after three days of
continuous NGF administration. The level of septal ChAT
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activity in AF64A/NGF treated rats peaked at 14 days

(279~

of control) and decreased slightly (to 235% of control) by
28 days. VEH/NGF treated rats had an increase in septal ChAT
activity (147% of control) after seven days of continuous
NGF administration and this activity remained elevated up to
28 days.
These data indicate that i.c.v. administration of NGF
induces rapid changes in cholinergic phenotypic markers in
the SHP of both normal and AF64A treated rats.

Introduction
Many studies have shown that in vivo, i.c.v. NGF
administration produces changes in cholinergic phenotypic
markers. These changes occur in both normal and FF
transected rats. Fourteen day i.c.v. administration of NGF
to normal, intact rats, increased ChAT activity in the
septum and hippocampus (Fusco et al. 1989; Vantini et al.
1988). Whether NGF's action on cholinergic neurons in normal
rats also occurs with longer or shorter lengths of
administration has not been previously determined.
NGF attenuates the loss of cholinergic phenotypic
markers such as ChAT-IR, AChE staining as well as ChAT and
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AChE activity, in the septum and hippocampus of FF
transected rats (Lapchak and Hefti 1991; Hefti 1986; Montero
and Hefti 1988; Kromer et al. 1987; Williams, Jodalis and
Donald 1989) . In these studies, NGF administration varied
between 3 thru 28 days. The evaluation of NGF administration
on decreased hippocampal cholinergic enzyme activity has
only been done over a 21 day treatment period (Lapchak and
Hefti 1991) . Evaluation of the action of NGF on hippocampal
enzyme activity in rats with decreased cholinergic
phenotypic markers over shorter time periods has not been
previously determined.
AF64A is a toxin which, when administered by i.c.v.
injection and at specific doses, is selective for
cholinergic neurons in the SHP. AF64A has been previously
shown to reduce cholinergic enzyme activity (ChAT and AChE)
as well as HAChT in the hippocampus (Potter et al. 1989; El
Tamer et al. 1992; Chrobak et al. 1988; Chrobak et al. 1987;
Ikegami et al. 1989; Opello 1993). Previous work with NGF in
AF64A treated rats indicates that 14 day treatment does not
alter AF64A induced reduction of hippocampal cholinergic
phenotypic markers (Potter and Morrison 1991; Johnson et al.
1988). Cholinergic enzyme actiYity in the septum of AF64A
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treated rats has also been shown to be hyper-sensitive to
the action of NGF (Willson and Hanin, in press) . Whether NGF
administration for longer than 14 days (i.e. 28 days)
produce changes in cholinergic enzyme activity in either
normal or AF64A treated rats has not been previously
determined.
NGF administration for 14 days has been previously
shown to attenuate the normal weight gain that occurs in
rats (Lapchak and Hefti 1992; Williams and Oostveen 1992)
Whether this attenuation in normal weight gain continues
with longer periods of administration has not been
investigated.
The present study investigated the effects of i.c.v.
NGF administration, over various lengths of time, on
cholinergic enzyme activity in both normal and AF64A treated
rats. In addition, changes in weight gain were also
evaluated in these rats. The current study indicates that as
early as three days after continuous NGF infusion to AF64A
treated rats, a stimulation of enzyme activity occurs in
cholinergic neurons of the SHP. This increase in activity
remained even in rats treated with NGF continuously for 28
days. In addition, NGF administration resulted in weight
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loss after three days of continuous administration. Even
after 28 days, the weight gain in NGF treated rats was not
comparable to the weight gain that occurred in the control
rats.

Materials and Methods
Animals
Adult, male Sprague-Dawley rats (Zivic Miller
Laboratories, Allison Park, PA.) weighing between 200-310
grams were used for this study. The rats were housed two per
cage in a room on a 12 hour light cycle and had access to
food and water ad libitum. A total of 160 rats were used in
this experiment. Rats treated with NGF for three days were
weighed at the time of surgery and at the time of sacrifice.
All other rats were weighed at the time of surgery and every
seven days thereafter until they were killed. All rats were
used under according to IACUC specifications.

AF64A
AF64A was prepared according to standard procedures
(Fisher et al. 1982). Briefly, acetyl ethylcholine mustard
hydrochloride (UCB, Belgium) was dissolved in water to a

124
concentration of 1 mM. This solution was adjusted to pH 11.5
with sodium hydroxide (NaOH; 1M-6M) and stirred for 20
minutes at room temperature. The solution was then adjusted
to pH 7.3 with hydrochloric acid (HCl; 1M-6M) and stirred at
room temperature for one hour. This solution was prepared
fresh before each experiment and kept on ice. Preparation of
AF64A in this manner produces

85-90~

cyclization of the

aziridinium ring (Gill and Rang 1966; El Tamer et al. 1992)

Surgical Procedures And Drug Treatment
Rats were anesthetized with equitensin (3ml/kg)
administered by intraperitoneal injection, placed into a
stereotaxic apparatus (Kopf) and their skull was exposed.
Either VEH (water, pH 7.3) or AF64A (1.5 nmol) was
administered bilaterally, one side at a time, into the
lateral ventricles at the coordinates of: -0.8 mm posterior,

+/- 1.5 mm lateral, and -4.0 mm ventral to bregma (Paxinos
and Watson 1986). One hour after the i.c.v. injection of
either VEH or AF64A, a sterile cannula-osmotic pump assembly
(Alza, Palo Alto, CA), filled with either cytochrome C (CC;
a control protein) (40 µg; 3.24 nmol) or NGF (40 µg; 3.08
nmol total) (Harlan Bioproducts, Indianapolis, IN) dissolved
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in artificial cerebrospinal fluid (NaCl, 123 mM; CaC1 2 ,
mM; KCl, 3.0 mM; MgC1 2 ,
mM and Na 2 HP0 4 ,

0.89 rnM; NaHC0 3 ,

0.25 rnM) containing

l~

25 mM; NaH 2 P0 4 ,

0.86
0.5

bovine serum albumin

and pre-equilibrated for at least three hours in sterile
saline at 37°C was implanted subcutaneously on the animal's
back. The tip of the cannula was stereotaxically lowered
into either the right or left lateral ventricle. The cannula
was affixed to the skull, via an anchoring screw, with
dental cement (Coralite Dental Products, Skokie, Il). The
wound was closed and the rats were administered 0.3 ml
(50 mg/ml) ampicillin subcutaneously. The NGF dose used was
based on the increase in cholinergic enzyme activity at this
dose in chapter IV. In this experiment, the four treatment
groups; VEH/CC, AF64A/CC, AF64A/NGF and VEH/NGF were treated
continuously for either 3, 7, 14 or 28 days. Rats treated
over 28 days had their pumps replaced after 14 days with
fresh pumps containing the identical substance initially
administered. At the end of the treatment period the rats
were killed by decapitation and the brains were dissected on
ice. The hippocampal and septal tissue was immediately
placed on dry ice and subseguently stored at -70°C.
An additional group of rats,

containing all four
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treatment groups were treated similarly to the rats in the
28 day time period except that, NGF was administered for
only 14 days. On day 14, all rats had their pumps replaced
with CC filled pumps. The CC was administered for an
additional 14 days. Rats in this 14 day NGF treatment/28 day
survival paradigm were killed on day 28 and the hippocampus
and septum were removed as described above. There were seven
to eight rats in each group at each time point since six
rats died during the course of the experiment.

ENZYME ASSAY
Tissue preparation
The hippocampus and septum were thawed in ice cold
sodium phosphate buffer 75 mM, pH 7.4,

(1 ml for hippocampal

tissue and 0.6 ml for septal tissue) and homogenized (20
sec. @ setting 5 on a Polytron homogenizer model # PT
10/35).

ChAT activity
The ChAT assay followed the Fonnum method (1975). In
brief, 10 µl of tissue homogenate was added to 10 µl of
buffer substrate [cold sodium phosphate, 75 mM pH 7.4; NaCl,
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600 mM; MgC1 2 , 40 mM; eserine, 2.0 mM; bovine serum albumin,
0.05%; choline-iodide, 10 mM; and [ 3 H]acetyl coenzyme A,
0.87 mM

(=

20 mCi/mmol)]. This mixture was then incubated

for 30 minutes at 37°C and the tubes placed on crushed ice
following incubation. One hundred and fifty µl of sodium
tetraphenylboron solution (75 mg/ml in 3-heptanone) was
added to each tube and the tubes were vortexed and
centrifuged. After centrifugation, 100 µl of the organic
(top)

layer was removed and placed into scintillation vials.

Ten milliliters of scintillation cocktail was added and the
vials were counted using liquid scintillation spectrometry.
The level of ChAT activity was measured by subtracting the
disintegrations per minute (dpm) in the blank tubes (without
the tissue)

from the dpm in the tubes with tissue.

AChE activity
The AChE assay is similar to the ChAT assay, but with
the following modifications (Leventer et al. 1985). Tissue
homogenate (10 µl) was added to 20 µl of buffer substrate
[cold sodium phosphate buffer, 75mM, pH 7.0; AChI, lOmM and
[

3

H]ACh iodide 10 mM (= 8 mCi/mmol)]. This mixture was

incubated for 20 minutes at 37°C and the tubes were then
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placed into crushed ice. Ice cold water (30 µl)

was then

added to each tube followed by 150 µl sodium tetraphenylboron solution (75 mg/ml in 3-heptanone) . The tubes were
then vortexed, centrifuged, and frozen for 30 minutes at
-20°c. When removed from the freezer the organic

was discarded and the aqueous

(top)

layer

(bottom) layer thawed. Thirty

µl of this aqueous layer was placed into scintillation vials
and 10 ml of scintillation cocktail was added. These vials,
along with blank tubes (assay without tissue substrate),
were counted using a liquid scintillation spectrometer. The
level of AChE activity was calculated by subtracting the dpm
in the blank tubes from the dpm in the assay tubes with
tissue.

Protein Determination
Tissue protein levels were assessed by the method of
Lowry et al. (1951) for both the ChAT and AChE assays.

Statistical Analysis
The level of enzyme activity in the rats is expressed
as either nmol/mg/hr or % control. The values indicated are
means ± SEM of 7-8 rats per treatment group at each time
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point. The data were analyzed by two way ANOVA followed by
post-hoc analysis (Fisher LSD). The changes in the weights
of the rats are expressed as the % mean ± SEM of the rats'
initial weight. The data were analyzed by ANOVA with posthoc analysis (Fisher LSD) . The data from the VEH/CC and
AF64A/CC treated rats in the 14 day NGF treatment/28 day
survival paradigm were combined with the 28 day continuously
treated rats for purposes of statistical analysis and
therefore each treatment group (VEH/CC or AF64A/CC)
contained 15 rats.

Results
In the hippocarnpus, there was a significant main effect
of treatment group (f=45.53, p=0.000, df=4) and length of
NGF administration (f=12.21, p=0.000, df=4) on ChAT
activity. There was no interaction between the treatment
group and the length of NGP administration (f=l.73, p=0.067,
df=4). ChAT activity was significantly reduced (p< 0.01) in
the hippocampus of AF64A/CC treated rats at 3, 7, 14 and 28
days. AF64A/CC treatment decreased ChAT activity to 45%,
58%, 63% and 71% of control
respectively (fig. 19).

(VEH/CC) for these times
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Fig. 19. ChAT activity was measured in the hippocampus. VEH
(water) or AF64A (1.5 nmol/ventricle) was injected into the
lateral ventricle followed by continuous administration of
CC (3.24 nmol; 40 µg) or NGF (3.08 nmol; 40 µg) for either
3, 7, 14 or 28 days. There were 7-8 rats per groups at each
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05
compared with AF64A/CC and #,p< 0.05 compared with VEH/NGF.
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AF64A/NGF treated rats had similar declines in ChAT activity
with the exception of rats treated for 28 days. At the 28
day time point, hippocampal ChAT activity increased to 107%
of control and was significantly greater (P=0.003) than the
level of activity in AF64A/CC treated rats. Hippocampal ChAT
activity in VEH/NGF treated rats increased significantly (p<
0.05) by 34% and 26% of control at 7 and 28 days respectively. The enzyme activity in all treatment groups of rats
surviving 28 days was significantly (p< 0.05) greater
compared with those surviving three days.
In the septum, a significant difference was found in
ChAT activity between the treatment groups (f=48.45, p=0.000
df=3) but, not the various lengths of NGF administration
(f=l.52, p=0.20, df=4). The interaction (f=l.57, p=0.108,
df=l2) between treatment group and length of NGF
administration was also non-significant. Septal ChAT
activity was significantly increased (p< 0.01) in AF64A/NGF
treated rats regardless of the length of treatment (fig.
20). This increase in septal ChAT activity (179% of control)
began at day 3 and peaked at day 14 (279% of control) . Rats
treated for 28 days with AF64A/NGF showed a non-significant
reduction in ChAT activity (reduced to 235% of control) .
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Fig. 20. ChAT activity was measured in the septum. VEH
(water) or AF64A (1.5 nmol/ventricle) was injected into the
lateral ventricle followed by continuous administration of
CC (3.24 nmol; 40 µg) or NGP (3.08 nmol; 40 µg) for either
3, 7, 14 or 28 days. There were 7-8 rats per groups at each
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05
compared with AF64A/CC and #, p< 0.05 compared with VEH/NGF.
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AF64A/CC treatment alone produced a non-significant increase
(132% of control) in septal ChAT activity seven days after
CC administration. At all other time points, ChAT activity
in this treatment group remained at control levels. NGF
alone (in VEH/NGF treated rats) increased septal ChAT
activity (p< 0.05) 147%, 144% and 159% of control in rats
treated for 7, 14 and 28 days respectively. The level of
ChAT activity in VEH/NGF treated rats was significantly
(p< 0.05) lower than in the AF64A/NGF treated at all time
points.
In the hippocampus there was a significant difference
in AChE activity among the various treatment groups
(f=24.87, p=0.000, df=3). The length of treatment did not
alter hippocampal AChE activity (f=l.76, p=0.139, df=4).
Across all treatment times, AF64A/CC significantly reduced
(p< 0.01) (from 45%-63% of control for 3 and 28 days
respectively) enzyme activity (fig. 21). Acetylcholinesterase activity in AF64A/NGF treated rats was similar,
over the entire 28 days, to levels in AF64A/CC treated rats.
Acetylcholinesterase activity in the VEH/NGF treated rats
(83%-109% of control) was not significantly different from
control rats.
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Fig. 21. AChE activity was measured in the hippocampus. VEH
(water) or AF64A (1.5 nmol/ventricle) was injected into the
lateral ventricle followed by continuous administration of
CC (3.24 nmol; 40 µg) or NGF (3.08 nmol; 40 µg) for either
3, 7, 14 or 28 days. There were 7-8 rats per groups at each
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05
compared with AF64A/CC and#, p< 0.05 compared with VEH/NGF.
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In the septum, AChE activity was significantly
different among the treatment groups (f=28.04, p=0.000,
df=3) but did not change with different lengths of treatment
(f=l.05, p=0.38, df=4). Septal AChE activity in AF64A/NGF
treated rats increased significantly (p< 0.01) after 14 and
28 days of treatment (227% and 211% of control respectively)
but, the level of enzyme activity at 3 and 7 days was
unchanged (fig. 22). As with ChAT activity in AF64A/NGF
treated rats, AChE activity peaked at day 14 and this
increase began to decrease by 28 days. Septal AChE activity
in the AF64A/CC and VEH/NGF treated rats was not
significantly different at the 3, 7, or 14 day time point
compared with control rats. Rats treated with VEH/NGF for 28
days had a significant (p=0.028) increase in activity
compared with controls. In addition, septal AChE activity in
AF64A/NGF treated rats was significantly greater (p< 0.01)
at 14 and 28 days than the activity in VEH/NGF treated rats.
In rats treated with NGF for 14 days and then allowed
to survive an additional 14 days (28 days survival
paradigm), there was a significant change in ChAT activity
between treatment groups (f=7.43, p=0.000, df=3).
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Fig. 22. AChE activity was measured in the septum. VEH
(water) or AF64A (1.5 nmol/ventricle) was injected into the
lateral ventricle followed by continuous administration of
CC (3.24 nmol; 40 µg) or NGF (3.08 nmol; 40 µg) for either
3, 7, 14 or 28 days. There were 7-8 rats per groups at each
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05
compared with AF64A/CC and#, p< 0.05 compared with VEH/NGF.
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ChAT activity was significantly (p< 0.01) decreased in
hippocampus of AF64A/CC and AF64A/NGF treated rats (fig.
23). VEH/NGF treatment did not alter ChAT activity compared
with VEH/CC treated rats. Hippocampal ChAT activity in rats
treated with AF64A/NGF for 14 days and allowed to survive an
additional 14 days was significantly (p=0.001) different
from the level of activity in rats treated with NGF for 28
days continuously. The continuously treated rats increased
their ChAT activity (to 107% of control) while the level of
ChAT activity in rats treated for only 14 days remained
decreased (63% of control) .
There was a main effect of treatment group in septal
ChAT activity (f=13.13, p=0.000, df=3). In both the
AF64A/NGF or VEH/NGF treatment groups there was no
difference in septal ChAT activity between rats in the 14
day NGF treatment/28 day survival paradigm and those treated
for 28 days continuously. Rats in the 14 day NGF
treatment/28 day survival paradigm treated with AF64A/NGF
had a significant (p=0.000) increase (201% of VEH/CC) in
septal ChAT activity (fig. 24).
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Fig. 23. ChAT activity in the hippocampus of rats in a 28
day continuous NGF treatment paradigm and rats in a 14 day
NGF administration/28 day total survival paradigm. VEH
(water) or AF64A (1.5 nmol/ventricle) was injected into the
lateral ventricle followed by administration of CC (3.24
nmol; 40 µg) or NGF (3.08 nrnol; 40 µg} for 28 days
continuously or 14 days. Values from the VEH/CC and AF64A/CC
treated rats were combined. There are 15-16 rats in the
VEH/CC and AF64A/CC treated groups. There are seven-eight
rats in all other groups. *, P< 0.05 compared with VEH/CC;
#, p< 0.05 compared with VEH/NGP and##, p< 0.05 compared
with 28 day treated rats.
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Fig. 24. ChAT activity in the septum of rats in a 28 day
continuous NGF treatment paradigm and rats in a 14 day NGF
administration/28 day total survival paradigm. VEH (water)
or AF64A (1.5 nmol/ventricle) was injected into the lateral
ventricle followed by administration of CC (3.24 nmol; 40
µg) or NGF (3.08 nmol; 40 ~g) for 28 days continuously or 14
days. Values from the VEH/CC and AF64A/CC treated rats were
combined. There are 15-16 rats in the VEH/CC and AF64A/CC
treated groups. There are seven-eight rats in all other
groups. *, p< 0.05 compared with VEH/CC; **, p< 0.05
compared with AF64A/CC and#, p< 0.05 compared with VEH/NGF
treated rats.
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AChE activity in the hippocampus of rats in the 14 day
NGF treatment/28 day survival paradigm were significantly
different among treatment groups (f=B.51, p=0.000, df=3).
AChE activity was significantly (p< 0.01) reduced in the
hippocampus of AF64A/CC and AF64A/NGF (to 63% and 53% of
VEH/CC respectively) rats (fig. 25). The AF64A/CC and
AF64A/NGF treated rats did not differ in hippocampal AChE
activity. Further, there was no difference between the two
treatment paradigms NGF alone (VEH/NGF) did not increase
AChE activity in either of the two treatment paradigms.
Septal AChE activity was significantly different among
the four treatment groups (f=16.21, p=0.000, df=3). Septal
AChE activity in rats treated with AF64A/NGF for 14 days and
then allowed to survive an additional 14 days increased
significantly (p=0.000)

(235~ of

VEH/CC) compared with VEH/CC

and AF64A/CC treated rats (fig. 26). This change in septal
AChE activity was similar to that in rats treated with
AF64A/NGF continuously for the entire 28 days. The level of
septal AChE activity in rats treated with VEH/NGF in the 14
day treatment/28 days survival paradigm did not significantly change and was similar to that found in rats treated
with NGF continuously for 28 days.
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Fig. 25. AChE activity in the hippocampus of rats in a 28
day continuous NGF treatment paradigm and rats in a 14 day
NGF administration/28 day total survival paradigm. VEH
(water) or AF64A (1.5 nmol/ventricle) was injected into the
lateral ventricle followed by administration of CC (3.24
nmol; 40 ~g) or NGF (3.08 nmol; 40 µg) for 28 days
continuously or 14 days. Values from the VEH/CC and AF64A/CC
treated rats were combined. There are 15-16 rats in the
VEH/CC and AF64A/CC treated groups. There are seven-eight
rats in all other groups. *, p< 0.05 compared with VEH/CC
and#, p< 0.05 compared with VEH/NGF.
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Fig. 26. AChE activity in the septum of rats in a 28 day
continuous NGF treatment paradigm and rats in a 14 day NGF
administration/28 day total survival paradigm. VEH (water)
or AF64A (1.5 nmol/ventricle) was injected into the lateral
ventricle followed by administration of CC (3.24 nmol; 40
µg) or NGF (3.08 nmol; 40 µg) for 28 days continuously or 14
days. Values from the VEH/CC and AF64A/CC treated rats were
combined. There are 15-16 rats in the VEH/CC and AF64A/CC
treated groups. There are seven-eight rats in all other
groups. *, p< 0.05 compared with VEH/CC; and#, p< 0.05
compared with VEH/NGF.
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At the time of surgery, all rats had similar weights
(f=0.93, p=0.428, df=3). After three days of treatment, the
AF64A/NGF and VEH/NGF treated rats significantly (p< 0.01)
decreased their weight compared with VEH/CC treated rats
(table 5) . Similar to the VEH/CC treated rats, AF64A/CC
treated rats maintained their weight (95%) compared with
their initial weight. By day seven, all treatment groups
showed increased weight gain and all rats increased their
weight over the 28 days of treatment. Although the AF64A/NGF
and VEH/NGF treated rats gained weight, they still weighed
significantly less than VER/CC treated rats at all time
points (P< 0.05). In addition, rats treated with AF64A/NGF
or VEH/NGF for 14 days and then allowed to survive an
additional 14 days (28 days total) had significantly
(p< 0.05) less weight gain on day 21 than VEH/CC treated
rats . By day 28, their weight gain was comparable to VEH/CC
treated rats (table 5) . This differed from rats treated
continuously with NGF since they which had significantly
(p< 0.01) less weight gain than VEH/CC treated rats. In both
the 14 day NGF treatment/28 day survival paradigm and the 28
day NGF continuously treated rats, there was no significant
difference between the VEH/CC and AF64A/CC treated rats.

Table 5.-- Changes in Weight over Time by Treatment Groups
TREATMENT GROUPS
VEH/CC

AF64A/CC

AF64A/NGF

VEH/NGF

3 days

98 (l.26)

95 (2.34)

89 (2.68)**

92(2.10 )**

7 days

115 (1.19)

109 (1.48)

102 (l.45) **

110 (1.12)**

14 days

137 (1. 80)

132 (2. 29

110 (2.59)**

120 (3.19)**

21 days

155 (3.61)

148 ( 3. 71)

125 (6.57)**

140 (5.87)**

28 days

172 (4. 80)

166 ( 4. 64)

145 (8.57)**

155 (7.11)**

14 days NGF/ 28 days survival rats
21 days

155 (3.61)

148 (3.71)

136 (5.31)**

145 (6.06)*

28 days

172 (4.80)

166 (4.64)

160 (6.04)

168 ( 8. 11)

Data are represented as the mean ± SEM % of the rats' initial weight at the time of
surgery. * P < 0.05 and ** p < 0.01 compared with the VEH/CC rats.

I-'

,p.
,p.
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Discussion
In the present study, septal ChAT activity in AF64A
treated rats is hyper-sensitive to NGF as early as three
days after the beginning of treatment and continues up to 28
days. After seven days of AF64A/NGF treatment, a large
increase in ChAT activity which peaked at day 14 was found.
Septal AChE activity in AF64A treated rats was also hypersensitive to NGF, but this sensitivity took longer to occur
(14 days) . AF64A treated rats, regardless of whether their
treatment was followed by CC or NGP administration, had a
decrease in hippocampal cholinergic enzyme activity. These
results agree with previous work showing that AF64A acts on
the cholinergic terminals in the hippocampus and reduces
cholinergic enzyme activity, BAChT, and ACh levels (El Tamer
et al. 1992; Potter and Morrison 1991; Fisher et al. 1982).
The reduction in enzyme activity occurred as early as three
days after AF64A treatment. Previous work has shown that two
days after AF64A injection, ACh levels are reduced 50% in
the hippocampus (Hortnagl et al. 1987a). Reduction of
hippocampal ChAT and AChE activity, as well as HAChT,
occurred four days after AF64A treatment (El Tamer et al.
1992). In the present study, AF64A induced decreases in
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hippocampal enzyme activity were not reversed after either
3, 7 or 14 days of continuous NGF administration. In
contrast, the AF64A/NGF rats showed a large increase in
hippocampal enzyme activity between 14 and 28 days which
resulted in a complete recovery of ChAT activity by 28 days.
AF64A treated rats, continuously administered NGF for 28
days, had a higher level of hippocampal ChAT activity
compared with AF64A/CC treated rats and suggests that NGF
can accelerate the recovery of cholinergic enzyme activity
that occurs in AF64A treated rats at longer time points (El
Tamer et al. 1992).
The temporal changes in hippocampal and septal ChAT
activity in the current study are consistent with the
concept that, ChAT mRNA is localized in the septum but not
the hippocampus (Ibanez, Ernfors and Persson 1991;
Cavicchioli et al. 1991) and therefore, the ChAT protein
must be antrogradely transported to the terminals in the
hippocampus. The increase in septal ChAT activity prior to
(between 7 and 14 days) changes in hippocampal activity
(between 14 and 28 days)

in AF64A/NGF treated rats suggest

that, recovery of hippocampal ChAT activity after 28 days of
NGF administration may be due to the stimulation of ChAT
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synthesis in the septum.
Rats treated with VEH/NGF had an increase in ChAT
activity, but not AChE activity, in both the septum and
hippocampus. In both regions, the increases in ChAT activity
occurred simultaneously after seven days of continuous NGF
administration. In comparison, 14 day administration of NGF
to normal rats has been shown to produce an increase in ChAT
activity in the septum and hippocampus (Fusco et al. 1989;
Vantini et al. 1988). NGF administration to normal rats did
not alter AChE activity (Fusco et al. 1989; Vantini et al.
1988) . The data in the present study indicate that, in
addition to increasing the sensitivity of cholinergic
neurons of the SHP to exogenous NGF, AF64A treatment also
reduces the length of NGF administration necessary to
stimulate ChAT activity.
Rats treated with NGF for 14 days and then allowed to
survive an additional 14 days had a reduction in hippocampal
ChAT and AChE activity in both AF64A/NGF and AF64A/CC
treated rats. AF64A/NGF treated rats in this 14 days
treatment/28 day survival paradigm had a decreased level of
hippocampal enzyme activity while rats continuously treated
with NGF for 28 days had levels of enzyme activity similar
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to control. In FF transected rats, continuous NGF
administration is necessary for recovery of AChE positive
cells in the septum. If NGF treatment is discontinued, but
the rats allowed to survive an additional four weeks, AChE
staining returns to levels similar to rats with FF
transections alone (Montero and Hefti 1988) . In addition,
when NGF administration to an Alzheimer patient was
discontinued in after three months of treatment, improvements in nicotinic binding and memory were no longer evident
(Olson et al. 1992). These data suggest that once NGF
administration is discontinued, changes in cholinergic
phenotypic markers do not persist and that continuous
administration is necessary.
Attenuation of weight gain in NGF treated rats occurred
after three days of administration and are probably due to
changes in food consumption. NGF administration decreased
food intake in rats as early as five days after the initiation of NGF infusion (Williams 1991). NGF's effect on
attenuating normal weight gain was greater in AF64A/NGF
treated rats than in VEH/NGF treated rats and further
suggests that AF64A treated rats are hypersensitivity to
exogenous NGF. Differences between AF64A/NGF and VEH/NGF
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treated rats cannot be accounted for by AF64A administration
alone since, AF64A/CC treated rats had weight gains
comparable to VEH/CC treated rats. In addition, the
attenuation in weight gain is NGF dependent since rats
treated with NGF for 14 days, but allowed to survive for 28
days, did not differ significantly in weight gain from
VEH/CC treated rats. This is not unexpected since normal or
FF transected rats treated with NGF over 14 days and then
allowed to survive an additional 14 days had increased
weight gain after NGF administration was discontinued
(Williams 199lb) .
The present study demonstrated that AF64A treated rats
have increased sensitivity to NGF, compared with VEH/NGF
treated rats, as early as three days after NGF administration is initiated. Further, this increase in enzyme activity
remained for up to 28 days. Further, if NGF treatment is
discontinued at 14 days, some of its actions (recovery in
the hippocampus and attenuation of weight gain) do not
persist after an additional 14 days. This indicates that in

vivo, NGF treatment must be continuous in order to stimulate
the recovery of AF64A induced decreases in cholinergic
phenotypic markers.

CHAPTER VI
EFFECT OF BDNF ON THE SEPTO-HIPPOCAMPAL PATHWAY OF NORMAL
AND ETHYLCHOLINE MUSTARD AZIRIDINIUM {AF64A) TREATED RATS.

Summary
In the present study, i.c.v. administration of BDNF
increased ChAT activity in the septum of AF64A (1.5
nmol/ventricle) treated rats. This response was dose
dependent since enzyme activity increased only in rats
treated with higher doses but not those treated with lower
doses. BDNF at doses of 0.8 nmol and 8.0 nmol produced a
126% of control increase in septal ChAT activity. Although
these two doses of BDNF in AF64A treated rats increased
cholinergic enzyme activity in the SHP, they did not affect
GAD activity. In normal rats, BDNF treatment did not affect
either cholinergic (ChAT and AChE) nor GABAergic (GAD)
enzyme activity. This indicates that, in these experiments,
BDNF selectively acted on cholinergic neurons which were
affected by AF64A.
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Introduction
Cholinergic neurons of the SHP are responsive to NGF
(for review see Levi-Montalcini 1987). Although NGF was the
first NTF isolated and is the most characterized, other
NTF's have now been isolated. One of these NTFs is BDNF
(Barde et al. 1982). Since its discovery, BDNF and its mRNA
have been localized to the dentate gyrus and cornu Ammonis
region of the hippocampus (Phillips et al. 1990; Kokaia et
al. 1993; Ernfors et al. 1990a). Further, the high affinity
receptor for BDNF, TrkB, is also localized to the hippocampus (Kokaia et al. 1993) and septum (Altar et al. 1994c).
The structural similarities between BDNF and NGF
(Leibrock et al. 1989) indicate that BDNF, like NGF, might
act on cholinergic neurons in the SHP. In vitro work has
confirmed that BDNF acts on cholinergic neurons. BDNF
administration increases cholinergic phenotypic markers such
as AChE staining, ChAT activity, and HAChT in septal cell
cultures (Alderson et al. 1990; Nonomura and Hatanaka 1992;
Knusel et al. 1992).
Recent work has evaluated the in vivo administration of
BDNF to FF transected rats and whether it can prevent the
loss of cholinergic neurons and their neuronal markers.
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Several studies have shown that i.c.v. or intraseptal BDNF
administration to rats can prevent FF transection induced
cholinergic cell loss in the septum (Knusel et al. 1992;
Morse et al. 1993). In contrast, other studies indicate that
i.c.v. administration of BDNF does not reverse decreases in
cholinergic phenotypic markers induced by FF transection
(Lapchak et al. 1992; Koliatsos et al. 1994). Therefore,
whether in vivo administration of BDNF affects cholinergic
neurons of the SHP is still unclear.
Although BDNF may be able to reverse the reduction of
cholinergic phenotypic markers that occurs in FF transected
rats, its action on normal, intact neurons has not been well
studied. The administration of a single dose (10 µg/week)

of

BDNF to normal rats has been shown not to change septal ChAT
enzyme activity (Koliatsos et al. 1994). If BDNF is to be
considered as a potential therapeutic agent for neurodegenerative diseases, a complete evaluation of its action on
cholinergic neurons of normal rats, at a variety of doses,
is necessary.
AF64A is a toxin which has been shown to be selective,
in a dose dependent manner, for cholinergic neurons in the
SHP (El Tamer et al. 1992; Hortnagl et al. 1987a,b). Using
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this toxin, the ability to of BDNF reverse or prevent
changes in cholinergic phenotypic markers in the SHP after
AF64A administration can be assessed. In addition,
cholinergic neurons of the SHP have been previously shown to
be more responsive to NGF after AF64A treatment (Willson and
Hanin, in press) . Whether SHP cholinergic neurons of AF64A
treated rats are also more responsive to BDNF treatment is
unknown.
In the present work, the in vivo effects of BDNF on
cholinergic enzyme activity in the SHP of normal and AF64A
treated rats were evaluated. Further, in order to evaluate
whether BDNFs action is restricted to cholinergic neurons or
a more generalized effect of neuronal stimulation, the
activity of the GABAergic synthesizing enzyme, GAD, was also
evaluated.

Materials and Methods
Animals
Adult, male Sprague-Dawley rats (Zivic Miller
Laboratories, Allison Park, PA.) weighing between
218-372 grams were used for this study. A total of 88 rats
were used in this study. The rats were housed two per cage
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in a room on a 12 hour light cycle and had access to food
and water ad libitum. The rats were weighed at the time of
surgery and once every week till they were sacrificed.

AF64A
AF64A was prepared according to standard methods
(Fisher et al. 1982). Acetyl ethylcholine mustard
hydrochloride (UCB, Belgium) was dissolved in water to a
concentration of 1 mM. This solution was adjusted to pH 11.5
with sodium hydroxide

(NaOH; 1M-6M) and stirred for 20

minutes at room temperature. The solution was then adjusted
to pH 7.3 with hydrochloric acid (HCl; 1M-6M) and stirred at
room temperature for one hour. This solution was prepared
fresh before each experiment and kept on ice. Preparation of
AF64A in this manner produces 85-90% cyclization of the
aziridinium ring (Gill and Rang 1966; El Tamer et al. 1992).

Surgical Procedures and Drug Treatment
All rats were anesthetized with equitensin (3ml/kg)
administered by intraperitoneal injection. The rats were
placed into a stereotaxic apparatus (Kopf) and their skull
was exposed.
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Dose response studies
In the dose-response experiment in normal rats, rats
were sham operated by having two needles (26 gauge)

lowered

into the lateral ventricles through two holes drilled at the
coordinates of: -0.8 mm posterior, +/- 1.5 mm lateral, and 4.0 mm ventral to bregma (Paxinos and Watson 1986). The
needles were left in place for one minute and then removed.
A sterile cannula-osmotic pump assembly (Alza, Palo Alto,
CA) was filled with either cytochrome C (CC; a control
protein) or recombinant BDNF (a gift from Regeneron
Pharmaceuticals, Tarrytown, NY) dissolved in artificial
cerebrospinal fluid (NaCl, 123 mM; CaC1 2 , 0.86 mM; KCl, 3.0
mM; MgC1 2 ,

0. 89 mM; NaHC0 3 , 25 mM; NaH 2 P04 , 0. 5 mM; and Na 2 HP0 4 ,

0.25 mM) containing 1% bovine serum albumin. This level of
serum albumin was recommended by Regeneron when using lower
doses of BDNF as in the current study. The cannula-pump
assembly had been pre-equilibrated for at least three hours
in sterile saline at 37°C. The osmotic pump was implanted
subcutaneously on the animal's back and the tip of the
cannula was stereotaxically lowered into either the right or
left lateral ventricle. This was affixed to the skull, via
an anchoring screw, with dental cement (Coralite Dental
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Products, Skokie, Il). The wound was closed and the rats
were administered 0.3 ml (50 mg/ml) ampicillin
subcutaneously. In this experiment 40 rats were used
although two died before completion of the experiment.
In the dose-response experiment with AF64A treated
rats, the control rats (VER/CC) had water at pH 7.3 as
vehicle (VEH)

injected into the lateral ventricles (see

coordinates given above) . Rats in the AF64A treatment groups
had AF64A (1.5 nmol/ventricle) injected into their lateral
ventricles. These injections were bilateral, one side
injected at a time, at a rate of 0.5

~l

per minute. The

cannula-pump assembly was implanted as described for the
normal rats. Of the 48 rats in this experiment, two were
eliminated from the analysis due to post-surgical
complications and two rats died during the experiment.
In both experiments, CC (99

~g;

8.0 nmol total) or BDNF

(0.099-99 µg; 0.008-8.0 nmol total) was administered
continuously for 14 days. These doses were chosen because
previous work has shown that 90 µg BDNF can stimulate ChATIR in FF transected rats (Knusel et al. 1992). At the end of
the treatment the rats were sacrificed by decapitation and
the brains were dissected on ice. The tissue samples
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(hippocampus and septum) were immediately placed on dry ice
and subsequently stored at

-7o 0 c.

Enzyme Assays
Tissue preparation
The tissue (septum and hippocampus) was thawed in ice
cold sodium phosphate buffer 75 rn.M, pH 7.4,

(1 ml for

hippocampus and 0.6 ml for septum) and homogenized (20 sec.
@ setting 5 on a Polytron homogenizer model

# PT 10/35) . The

septal and hippocampal tissue homogenates were then divided
into two aliquots, one for the ChAT and AChE assays and the
other for the GAD assay. The ChAT/AChE homogenate was frozen
at -70°C until the assays were conducted. To the GAD
homogenate, 0.1% Triton XlOO and 2.5 mM
aminoethylisothiouronium bromide in 100 mM potassium
phosphate buffer (pH 7.2) was added.

GAD activity
Glutamic acid decarboxylase activity was determined by
[

3

H]GABA formation and cation exchange isolation (Maderdrut

1979). Twenty micro liters of tissue homogenate was added to
30 µl of buffer substrate containing: 500 µM, EDTA tetra-

158
sodium salt hydrate; 200 µM, pyridoxal-5'-phosphate; 12 mM,
glutamic acid and 10 mM, GABA in potassium phosphate buff er
(pH 7.2, 100 mM). This solution was spiked with [ 3 H]
glutamic acid for a specific activity of 0.27 µCi per assay.
The blanks, used to define non-specific activity, consisted
of tubes containing 20 µl of buff er substituted for the
tissue homogenate. The samples were incubated for 30 minutes
at 37°C and then placed on ice. Five hundred micro liters of
5% trichloroacetic acid was added and the tubes were
vortexed. The samples were loaded into columns containing
4 cm of 50W-X4 cation exchange resin (Bio-Rad Laboratories)
which had been equilibrated with 4 ml of 2N NaOH followed by
5 ml of 0.2M citric acid. In order to remove any nonspecific bound [ 3 H] glutamic acid, the columns were washed
with 9 ml of cold sodium citrate buffer (0.2M, pH 3.5) and
then [ 3 H] GABA was eluted by the addition of 4 ml of cold
sodium acetate (0.2M, pH 5.5) to the column. The eluate was
collected into scintillation vials and 12 ml of scintillation cocktail was added. The vials were counted and the
amount of specific activity was determined by subtracting
the dpms in the blanks from those in the samples.
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ChAT activity
The ChAT assay followed the Fonnum method (1975). In
brief, 10 µl of tissue homogenate was added to 10 µl of
buffer substrate [cold sodium phosphate, 75 mM pH 7.4; NaCl,
600 mM; MgC1 2 , 40 mM; eserine, 2.0 mM; bovine serum albumin,
0.05%; choline-iodide, 10 mM; and [ 3 H]acetyl coenzyme A,
0.87 mM (= 20 mCi/mmol)]. This mixture was then incubated
for 30 minutes at 37°C and the tubes placed on crushed ice
following incubation. One hundred and fifty microliter of
sodium tetraphenylboron solution (75 mg/ml in 3-heptanone)
was added to each tube and the tubes were vortexed and
centrifuged. After centrifugation, 100 µl of the organic
(top)

layer was removed and placed into scintillation vials.

Ten milliliters of scintillation cocktail was added and the
vials were counted using liquid scintillation spectrometry.
The level of ChAT activity was measured by subtracting the
disintegrations per minute (dpm)
tissue)

in the blank tubes (without

from the dpm in the tubes with tissue.

AChE activity
The AChE assay is similar to the ChAT assay, but with
the following modifications (Leventer et al. 1985). Tissue
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homogenate (10 µl)

was added to 20 µl of buffer substrate

[cold sodium phosphate buffer, 75mM, pH 7.0; AChI, lOmM and
[

3

H]ACh iodide 10 mM (= 8 mCi/mmol)]. This mixture was

incubated for 20 minutes at 37°C and the tubes were then
placed into crushed ice. Ice cold water (30 µl)

was then

added to each tube followed by 150 µl sodium tetraphenylboron solution (75 mg/ml in 3-heptanone) . The tubes
were then vortexed, centrifuged, and frozen for 30 minutes
at -20°C. When removed from the freezer the organic (top)
layer was discarded and the aqueous (bottom) layer thawed.
Thirty micro liters of this aqueous layer was placed into
scintillation vials and 10 ml of scintillation cocktail was
added. These vials, along with blank tubes (without tissue
substrate) , were counted using a liquid scintillation
spectrometer. The level of AChE activity was calculated by
subtracting the dpm in the blank tubes from the dpm in the
assay tubes with tissue.

Protein Determination
Tissue protein levels were assessed by the method of
Lowry et al.,

(1951)

for all three assays.
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Statistical Analysis
The levels of enzyme activity in the rats are
expressed as nmol/mg/hour. The values indicated in the text
and figures are means ± SEM. The data were analyzed by ANOVA
followed by post-hoc analysis (Fisher LSD) . Changes in the
weight of the rats are expressed as the % mean ± SEM of the
rats' initial weight and these data were analyzed by
repeated measures ANOVA.

Results
Enzyme Activity in Normal Rats
Cholinergic and GABAergic enzyme activities were
assessed in normal rats treated by i.c.v. injection with
various doses of BDNF (0.099-99 µg;

0.008-8 nmol total

administered continuously over 14 days). In the hippocampus,
ChAT, AChE, and GAD activity remained unchanged after BDNF
administration (f= 1.03, p=0.404, df=4; f=2.26, p=0.083, df=
4; f=l.34, p=0.276, df=4 respectively) (figs. 27, 28, 29). In
the septum, there was a slight, but non-significant,
increase in cholinergic enzyme activity (f=0.29, p=0.537,
df=4 for ChAT and f=l.00, p=0.42, df=4 for AChE) (figs. 27,
28) .
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Fig. 27. Dose response of BDNF in normal rats. BDNF or CC
(8 nmol) was infused i.c.v. over 14 days. Each point
represents the mean ± SEM of 7-8 rats per treatment group.
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Fig. 28. Dose response of BDNF in normal rats. BDNF or CC
(8 nmol) was infused i.c.v. over 14 days. Each point
represents the mean ± SEM of 7-8 rats per treatment group.
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Fig. 29. Dose response of BDNF in normal rats. BDNF or CC
(8 nmol) was infused i.c.v. over 14 days. Each point
represents the mean ± SEM of 7-8 rats per treatment group.
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GAD activity in this region was unaltered by BDNF (f=0.639,
p=0.639, df=4) (fig. 29).

Enzyme Activity in AF64A Treated Rats
Enzyme activity was assessed in the SHP of rats
initially treated with either VEH or AF64A, and then with
either CC (8.0 nmol) or BDNF (0.008-8.0 nmol over 14 days).
In the hippocampus, there was no significant change in ChAT
activity (f=l.84, p=0.128, df=5). AF64A/CC treatment
produced a non-significant, 27% reduction in hippocampal
ChAT activity. AF64A/BDNF treated rats did not show any
increase in hippocampal ChAT activity. This activity
remained decreased by 45% and

19~

of control for 0.008 and

8.0 nmol BDNF respectively (fig. 30). In the septal region,
there was a significant change in ChAT activity (f=S.32,
p=0.001, df=S). Septal ChAT activity in AF64A/CC treated
rats was similar to control levels. At the two highest doses
of BDNF (0.8 and 8.0 nmol), septal ChAT activity was
significantly (p< 0.01) increased 126% of control for both
doses (fig. 30).
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Fig 30. Rats were treated by i.c.v. injection with either
VEH (water) or AF64A (1.5 nmol/ventricle) followed by i.c.v.
infusion of either CC (8 nmol} or BDNF (0.008-8 nmol). Rats
were treated with CC or BDNF for 14 days. The data represent
the mean ChAT activity± SEM of 7-8 rats per group. *,
p< 0.05 compared with VEH/CC; and **, p< 0.01 compared with
AF64A/CC treated rats.
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In addition, these increases were significantly (p< 0.05)
greater than those in rats treated with lower doses of BDNF
(0.008 and 0.08 nmol) and indicates that BDNF affects ChAT
activity in a dose-dependent manner.
Hippocampal AChE activity was significantly altered in
the AF64A dose response experiment (f=6.304, p=0.000 df=5).
AChE activity in the hippocampus was significantly reduced
(41% of control) by AF64A/CC and remained decreased over all
four doses of BDNF (fig. 31). In the septum, AChE activity
was not significantly increased by treatment with either
AF64A/CC nor any dose of AF64A/BDNF (f=0.891, p 0.497,
df=5) (fig. 31).
Hippocampal GAD activity was unchanged by either
AF64A/CC or AF64A/BDNF treatment (f=l.081, p=0.386,
df=5) (fig. 32). GAD activity in the septum of AF64A/CC or
AF64A/BDNF treated rats was unchanged (f=2.155, p=0.080,
df=5) (fig. 32).
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Fig. 31. Rats were treated by i.c.v. injection with either
VEH (water) or AF64A (1.5 nmol/ventricle) followed by i.c.v.
infusion of either CC (8 nmol) or BDNF (0.008-8 nmol). Rats
were treated with CC or BDNF for 14 days. The data represent
the mean AChE activity ± SEM of 7-8 rats per group.
*, p< 0.05 compared with VEH/CC.
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Fig. 32. Rats were treated by i.c.v. injection with either
VEH (water) or AF64A (1.5 nmol/ventricle) followed by i.c.v.
infusion of either CC (8 nmol) or BDNF (0.008-8 nmol). Rats
were treated with CC or BDNF for 14 days. The data represent
the mean GAD activity ± SEM of 7-8 rats per group.
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Attenuation in Weight Gain of BDNF Treated Rats
In both experiments, rats were weighed at the time of
surgery and then once every week. Weight gain was altered
significantly in both normal (f=3.23, p=0.026, df=4) and
AF64A (f=3.42, p=0.012, df=S) treated rats which were
administered BDNF (Table 6). Normal rats treated with 8.0
nmol BDNF had a 4% reduction in weight over 14 days while
the control rats had a 32% weight gain. AF64A/BDNF (8.0
nmol) treated rats lost weight

(5~)

over the 14 day

treatment period compared with control rats (VEH/CC) which
had a 16% gain in their weight. AF64A/CC treatment did not
attenuate weight gain since these rats had increases in
their weight comparable to controls (table 6) .

Discussion
The present work demonstrates that in vivo
administration of BDNF into the lateral ventricle of normal
non-AF64A treated rats does not alter cholinergic enzyme
activity in the SHP. This is in agreement with work that
showed that, i.c.v. administration of BDNF did not alter
ChAT activity in normal rats (Koliatsos et al. 1994).
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Table 6.-- Changes in the weight of both normal and AF64A
treated rats.
TREATMENT

cc

WEIGHT-DAY 7

WEIGHT-DAY 14

107 ( 3. 68)

132

BDNF 0.008

110 ( 3 . 22)

136 (3.64)

BDNF 0.08

113

( 4. 77)

138 ( 3 . 94)

(5.21)*

104 (5.34)**

BDNF 0.8
BDNF 8

97

88

(13.01)*'1<

96

(3.69)

(5.61)**
(7.10)

VEH/CC

101 ( 6 .48)

116

AF64A/CC

104 ( 4. 71)

117 (7.52)
(4.07)

AF64A/BDNF 0.008

112

( 3. 26)

122

AF64A/BDNF 0.08

108

(3.80)

122 (4.28)

AF64A/BDNF 0.8

101 (5.23)

111 ( 6. 96)

AF64A/BDNF 8

89

( 5. 35)

95

(5.83)a

Rats were administered (i.c.v.) CC (8 nmol) or various
doses of BDNF. The mean ± SEM of the % of the initial
weight at the time of surgery are indicated. The top half
of the chart represents BDNF treatment in the normal rats
and the bottom half represents those treated with AF64A. *
P< 0.05 VS Cytochrome C; ~*, p < 0.01 vs CC; a, p < 0.01 VS
VEH/CC.
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Further, the data in the present study are in contrast to
the stimulation of septal and hippocampal ChAT activity
produced by NGF in normal rats (Willson and Hanin, in press;
Fusco et al. 1989). These data indicate that doses of BDNF
higher than those used in the present study may be necessary
to stimulate normal cholinergic neurons in the SHP.
The data in the present study indicate that cholinergic
neurons of the SHP may be more sensitive to BDNF after AF64A
treatment. In AF64A treated rats, i.c.v. BDNF administration
at doses of 0.8 and 8 nmol produced a significant increase
in septal ChAT activity. These results are similar to those
in AF64A/NGF treated rats where septal neurons were found to
be more responsive to NGP after AP64A treatment (Willson and
Hanin, in press) . Although similar doses of NGF and BDNF
(10 µg each; 0.76 and 0.8 nmol respectively) increase
cholinergic enzyme activity in septal neurons, these neurons
are more responsiveness to NGF (Willson and Hanin, in
press) . Neurons in the septal region of FF transected rats
are also more responsive to NGF than BDNF, when similar
doses are administered (Morse et al. 1993; Knusel et al.
1992) . In addition, dose response experiments in septal
cultures with NGF and BDNF have shown that NGF is 90 times
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more potent than BDNF in increasing ChAT activity (Knusel et
al. 1992).
AF64A/CC treatment did not alter septal cholinergic
enzyme activity at the 14 day time point used in the present
study. El Tamer et al.

(1992) has shown that AF64A produces

increased septal ChAT activity three to seven days after
AF64A administration and that the level of enzyme activity
returns to normal by 14 days. These data indicate that the
increase in ChAT activity in the septum of AF64A/BDNF
treated rats was due to the action of BDNF on these neurons
and not the stimulation of enzyme activity by AF64A.
AF64A/CC treatment produced a non-significant reduction
in the cholinergic enzyme activity in the hippocampus. Since
the action of AF64A is dose-dependent

(El Tamer et al.

1992), the immediate infusion of BDNF into the ventricle
after AF64A injection may have possibly diluted the dose of
AF64A received by the rat. The

27~

reduction in ChAT

activity is similar to the decrease in enzyme activity in
rats treated with lower doses of AF64A (El Tarner et al.
1992) .
Cholinergic enzyme activity in AF64A in treated rats
was not stimulated by i.c.v. administration of BNDF. In
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contrast, previous work has shown that other NTFs, such as
bFGF (Potter and Morrison 1991), as well as vitamin E, can
reverse AF64A induced decreases in cholinergic enzyme
activity (Johnson et al. 1988; Wortwein et al. 1994).
Further, in vivo BDNF administration can protect against
cholinergic neuronal atrophy in the septum that occurs after
FF transection (Knusel et al. 1992; Morse et al. 1993).
The data from the present study indicate that BDNF
administered by i.c.v. infusion did not affect GABAergic
neurons. Even at doses of BDNF that increased septal ChAT
activity, GAD activity in the SEP was not changed in
AF64A/BDNF treated rats. Previous work has demonstrated that
BDNF does not alter GAD mRNA in the medial septum of FF
transected rats (Koliatsos et al. 1994). In contrast,
supranigral infusions of BDNF increase GAD activity in the
superior colliculus (Altar et al. 1994a) but, do not alter
GABA uptake in the striatum of 6-0HDA lesioned rats (Altar
et al. 1994b). Although BDNF does not appear to interact
with GABAergic neurons, it does interact with dopaminergic
and serotonergic neurons of the nigrostriatal pathway (Altar
et al. 1994a; Altar et al. 1994b). The action of BDNF on
several neurotransmitter systems, as well as the
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localization of its mRNA (Ernfors et al. 1990a; Phillips et
al. 1990) and receptor (Yan et al. 1994; Altar et al.
1994c) , indicate that BDNF may act on multiple neuronal
populations.
In the present work, BDNF administration attenuated
normal weight gain in these rats. This inhibition of weight
gain was dose-dependent since rats administered lower doses
of BDNF (0.008 and 0.08 nmol) did not have a reduction in
the amount of weight they gained over the course of the
experiment. The attenuated weight gain was not due to AF64A
treatment since normal rats treated with BDNF also had

an

attenuation in weight gain. The changes in weight gain have
been postulated to be due to the direct action of BNDF on
TrkB receptors located in the hypothalamus (Lapchak and
Hefti 1992; Altar et al. 1994c). The changes in weight gain
in BDNF treated rats in the present study are similar to
those seen in NGF treated rats (Lapchak and Hefti 1992).
In conclusion, septal cholinergic neurons of AF64A
treated rats have an increased sensitivity to exogenously
administered BDNF. BDNFs action in the SHP of AF64A treated
rats is not a generalized effect on neuronal activity since
enzyme activity in GABAergic neurons is unaltered by BDNF.

CHAPTER VII
DISCUSSION

NTFs represent a relatively new group of proteins which
have been postulated to have future potential as therapeutic
agents in the treatment of neurodegenerative diseases. The

in vivo data in the current work increase our understanding
of the effects of NTFs in normal rats as well as those with
reduced cholinergic phenotypic markers. In the present work,
two hypotheses were tested: 1) exogenous NTFs, when administered in vivo to adult rats, stimulate ChAT and AChE
activity in normal cholinergic neurons; and

2) when

alterations in neuronal cholinergic enzyme activity are
created by AF64A, the effected neurons have an increased
sensitivity to exogenous NTF administration. In order to
address these two hypotheses, two specific aims were
formulated. The first specific aim was to study the effect
of i.c.v. administration of NGF and BDNF on normal cholinergic neurons of the SHP. NGF increased ChAT activity in
the hippocampus and septum by l42% and 149% of control,
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respectively. Changes in hippocampal activity occurred in a
dose-dependent manner. Further, i.c.v. administration of NGF
over 3, 7, 14 and 28 days produced increased ChAT activity
after seven days of administration. In contrast, BDNF, at
the doses used in the present work, did not alter cholinergic enzyme activity in the SHP of normal rats. This
suggests that normal cholinergic neurons of the SHP respond
differently to various NTPs. Neither NGF nor BDNF increased
AChE activity in the SHP of normal rats indicating that,
ChAT and AChE are differentially affected by NGF in normal
rats.
The change in ChAT activity,

induced by NGF, in normal

rats appears to be limited to cholinergic neurons and is not
a generalized phenomenon. This was evident from the
inability of NGF or BDNF to alter the level of GAD activity
in normal rats and suggests that GABAergic neurons of the
SHP are not sensitive to exogenous BDNF or NGF.
The second specific aim in the present work was
designed to investigate the effect of AF64A treatment on the
ability of in vivo NTF administration to alter cholinergic
enzyme activity in neurons of the SHP. This specific aim
addressed the question of whether AF64A treatment increases
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the sensitivity of cholinergic neurons in the SHP to
exogenous NTFs. In these experiments, the action of NGF,
BDNF, and bFGF on cholinergic enzyme activity in the septum
and hippocampus of AF64A treated rats was evaluated. In
addition, the action of NGF and BDNF on GAD activity in the
SHP of AF64A treated rats was evaluated.
In AF64A/NGF treated rats, AF64A treatment produced a
increased response in septal cholinergic enzyme activity NTF
administration. The response in AF64A treated rats to NGF
was greater (273%) than in normal, NGF treated rats (149%)
Septal cholinergic neurons in rats treated with AF64A also
demonstrated increased sensitivity to exogenous BDNF. The
increase in ChAT activity in these rats was less than in NGF
treated rats even though, the doses of BDNF used were
higher. In contrast, bFGF did not produce any increase in
cholinergic enzyme activity in the SHP of AF64A treated
rats. These data indicate that cholinergic neurons of the
septum are not as responsive to bFGF as they are to the
other two NTFs used in this work.
Other studies have also shown that rats with reduced
cholinergic phenotypic markers are more sensitive to NGF.
Rats with complete FF transections are "supersensitive" to
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NGF (Williams, Jodelis and Donald 1989). NGF increased ChAT
activity to a level 200% higher in FF transected rats than
in normal rats treated with NGF. This increase in sensitivity, as well as those in the current work, may be due to
the stimulation of endogenous NTPs. Lesioning the septum
increases endogenous NGP-like biological activity in the
hippocampus (as determined by bioassay, Scott et al. 1994).
FF transection produces an increase in hippocampal and
septal NGF (Weskamp et al. 1986). Further, chemical
substances, such as kainic acid, increase hippocampal NGF
mRNA expression (Gall, Murray and Isackson 1991). The
possibility therefore exists that AP64A treatment may
stimulate the production of endogenous NGF. An experiment
determining whether AP64A alters the endogenous level of NGF
or its mRNA would address this question.
The increase in cholinergic enzyme activity by NTFs in
the SHP of both normal and AF64A treated rats is probably
due to the stimulated production of mRNA for cholinergic
enzymes. NGF has been shown to increase ChAT mRNA levels in
the basal forebrain of normal rats (Cavicchioli et al. 1991;
Li et al. 1995). AF64A treatment increases both ChAT mRNA
(Fan et al. 1995) and ChAT activity in the septum (El Tamer
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et al. 1992). An increase in ChAT mRNA by AF64A, coupled
with increases produced by NGF, may account for the overall
increased level of ChAT activity in the septum of AF64A/NGF
treated rats in the present study. Experiments evaluating
changes in ChAT mRNA after AF64A/NGF treatment are required
in order to address this issue.
NGF treatment in AF64A treated rats produced recovery
in cholinergic enzyme activity after 28 days of continuous
NGF treatment. At this length of treatment, NGF administration increased enzyme activity to control levels. When
administered over 14 days 1 neither BDNF nor bFGF produced
any recovery of cholinergic enzyme activity in the hippocampus of AF64A treated rats. These two NTFs will have to be
tested over longer lengths of administration than used in
the current study before dismissing them as agents that can
reverse decreased enzyme activity.
AF64A treated rats are known to have working memory
deficits (Chrobak et al. 1987; Chrobak et al. 1988). NGF has
been shown to reverse memory deficits in aged rats and
therefore may also reverse behavioral changes induced by
AF64A (Fischer, Wictorin, and Bjorklund 1988). A future
experiment could evaluate whether rats treated with
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AF64A/NGF have any behavioral changes compared with AF64A/CC
treated rats.
NTFs have been previously proposed for the treatment of
neurodegenerative diseases. In vitro and in vivo work in
animals indicates that NTFs can reverse decreased neuronal
markers in several anatomical regions. NGF has been shown to
be important for cholinergic neurons of the basal forebrain
(Montero and Hefti, 1988; Hagg et al. 1989; Kromer 1987), an
area where decreased levels of cholinergic markers occur in
SDAT patients (Whitehouse et al. 1982; West et al. 1994).
NGF infusion into the lateral ventricle of a SDAT patient
has already been conducted. NGF was found to produce
recovery in nicotinic receptor binding in the frontal cortex
as well as improve performance on memory tasks (Olson et al.
1991). Although these results were promising, treatment had
to be discontinued due to pain experienced by the patient.
An

additional drawback to the use of NTFs as therapeutic

agents is the issue of whether they produce any aberrant
neuronal growth which may be detrimental to neuronal distribution and innervation. Further experiments will have to
be conducted in order to evaluate whether harmful growth
occurs with in vivo NTF administration.
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BDNF appears to also act on the dopaminergic system.
Studies with BDNF in rats treated with 6-0HDA demonstrate
that BDNF can produce a recovery in behavior and dopaminergic function (Altar et al. 1994b). Therefore, BDNF

may

provide a useful tool in the treatment of Parkinson's
disease (Lindsay et al. 1993). This diversity of action
indicates that NTFs may be important in a wide range of
neuronal systems but, that some specificity occurs.
The data from the present study indicate that bFGF may
not represent a promising therapeutic agent in neurodegenerative diseases. The lack of effect of bFGF in AF64A
treated rats compared with other NTFs (NGF and BDNF) suggest
indicate that this growth factor may act by a mechanism
different from that of NGF or BDNP.
In conclusion, the present work indicates that AF64A
treatment produces an increased responsiveness in cholinergic neurons to exogenous NTFs. The mechanism of this
increased sensitivity remains to be determined.
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